US Pat. No. 10,165,754

ANIMAL BATHING ASSEMBLY

1. An animal bathing assembly comprising:a housing being configured to have an animal placed therein;
a washing unit being coupled to said housing wherein said washing unit is configured to dispense a fluid onto the animal when the animal is positioned within said housing;
a plurality of scrubbing units, each of said scrubbing units being coupled to said housing wherein each of said scrubbing units is configured to scrub the animal when the animal is positioned within said housing;
a drying unit being coupled to said housing wherein said drying unit is configured to urge air onto the animal thereby facilitating the animal to be dried;
a control being coupled to said housing wherein said control is configured to be manipulated, said control being electrically coupled to said washing unit, said scrubbing unit and said drying unit such that said control controls operational parameters of said washing unit, said scrubbing unit and said drying unit;
each of said scrubbing units comprises a track having an upper end, a lower end and an outer wall extending between said upper end and said lower end, said track being substantially hollow, said outer wall having a front side and a back side, said front side of said track having a gear opening extending into an interior of said track, said gear opening extending between said upper end and said lower end;
said housing has an inner surface;
said gear opening has a lateral bounding edge, said lateral bounding edge comprising a plurality of teeth, said teeth being spaced apart from each other and being distributed along said lateral bounding edge, said back side of said track being coupled to said inner surface of said housing such that said track is vertically oriented;
a disk having a front surface and a back surface, said disk being substantially hollow, said front surface having a slot extending into an interior of said disk, said slot being continuous such that said slot forms a closed ring;
a motor being positioned within said interior of said track, said motor rotating in a first direction and a second direction; and
a first shaft being rotatably coupled to and extending away from said motor such that said motor rotates said first shaft when said motor is turned on, said first shaft extending outwardly from said gear opening and through said back surface of said disk, said first shaft having a distal end with respect to said motor, said distal end of said first shaft being positioned within said interior of said disk.

US Pat. No. 10,165,753

PET WATER FOUNTAIN

1. A pet water fountain comprising:a bucket configured to hold water;
a pump detachably mounted on a bottom of the bucket;
a cover body detachably mounted on a top of the bucket and covering the bucket, wherein the cover body has a lap edge corresponding to the shape of the top of the bucket and residing on the top of the bucket, and a first recess is formed in the center of the cover body, with a first hollow pipe which extends through to an inner space of the bucket being located in the center of the first recess, and a plurality of through holes being formed around the first hollow pipe, the cover body further has a first step surrounding a top of the first recess;
a filter contained in the first recess of the cover body surrounding the first hollow pipe;
a water platform mounted on the cover body, wherein the water platform has a second hollow pipe extending downwards through the first hollow pipe to connect a pump outlet of the pump, and the water platform has an inner flange surrounding the second hollow pipe and an outer flange, the inner flange being higher than the outer flange, and the water platform further has an outer sidewall extending downwards to be supported on the first step of the cover body, at least one gap being configured on a bottom of the outer sidewall to allow water overflowed from the outer flange of the water platform to flow through the at least one gap into the first recess and then flow back into the bucket after being filtered by the filter;
a flower nozzle mounted on the water platform, wherein the flower nozzle has a plurality of spouts along its periphery and has a third hollow pipe extending downwards from the center of the flower nozzle to be inserted into the second hollow pipe of the water platform, and the flower nozzle further has a top cover covering a top of the third hollow pipe, wherein water in the bucket is pumped upwards from the pump outlet into the second hollow pipe of the water platform and then into the third hollow pipe of the flower nozzle and then flows out from the spouts.

US Pat. No. 10,165,742

CENTER PIVOT IRRIGATION SYSTEM

1. A center pivot irrigation system having a center pivot, said system being for watering crops growing upon agricultural ground, said ground having a ground surface, said system comprising:(a) a plurality of towers which are rollable upon tower wheels, the plurality of towers being arranged in a series along a radial axis extending from the center pivot, each tower of the plurality of towers having a circumferential leg and a counter-circumferential leg, each tower wheel having a rotation axis substantially parallel to the radial axis;
(b) a plurality of circumferential pivot arms, each arm of the plurality of circumferential pivot arms having a distal end, each arm of the plurality of circumferential pivot arms having a proximal end which is pivotally attached to one of the circumferential legs;
(c) a plurality of counter-circumferential pivot arms, each arm of the plurality of counter-circumferential pivot arms having a distal end, each arm of the plurality of counter-circumferential pivot arms having a proximal end which is pivotally attached to one of the counter-circumferential legs;
(d) a plurality of circumferential linear motion actuators, each actuator of the plurality of circumferential linear motion actuators extending between one of the circumferential pivot arms and one of the circumferential legs, said each actuator being adapted for alternatively upwardly retracting and downwardly extending the one of the circumferential pivot arms;
(e) a plurality of counter-circumferential linear motion actuators, each actuator of the plurality of counter-circumferential linear motion actuators extending between one of the counter-circumferential pivot arms and one of the counter-circumferential legs, said each actuator being adapted for alternatively upwardly retracting and downwardly extending the one of the counter-circumferential pivot arms;
(f) a plurality of circumferential ground contact assemblies, each assembly of the plurality of circumferential ground contact assemblies being fixedly attached to the distal end of one of the circumferential pivot arms, said each assembly being adapted for, upon a downward extension of the one of the circumferential pivot arms, downwardly biasing against the ground surface; and
(g) a plurality of counter-circumferential ground contact assemblies, each assembly of the plurality of counter-circumferential ground contact assemblies being fixedly attached to the distal end of one of the counter-circumferential pivot arms, said each assembly being adapted for, upon a downward extension of the one of the counter-circumferential pivot arms, downwardly biasing against the ground surface, wherein each circumferential ground contact assembly comprises a circumferential ground contact member, wherein each counter-circumferential ground contact assembly comprises a counter-circumferential ground contact member, wherein each circumferential ground contact member comprises a circumferential ground contact wheel, wherein each counter-circumferential ground contact member comprises a counter-circumferential wheel, wherein each circumferential ground contact wheel has a rotation axis substantially parallel to the radial axis, and wherein each counter-circumferential ground contact wheel has a rotation axis substantially parallel with the radial axis.

US Pat. No. 10,165,740

TREE SAP COLLECTING DEVICE

ERATUBE INC., Saint-Hyac...

1. A tree sap collecting device, comprising:a main conduit extending between a first end insertable into a tree and a second end, the main conduit being hollow along at least some of a length thereof and defining an inner chamber extending from the first end toward the second end to receive sap; and
a hollow drainage conduit connected to the main conduit and extending away therefrom, the drainage conduit being in fluid communication with the inner chamber of the main conduit to receive sap therefrom, the drainage conduit having an outer surface and at least one protuberance extending outwardly from the outer surface, the at least one protuberance occupying a circumferential extent on the outer surface being less than a circumference of the outer surface, the outer surface being free of protrusions except for the at least one protuberance, the at least one protuberance engaging a collection tube upon the collection tube being mounted to the outer surface, the at least one protuberance locally radially deforming the collection tube upon the collection tube being mounted to the outer surface, a remainder of the collection tube remaining non-deformed so as to form deformed sections and non-deformed sections of the collection tube, an arrangement of the deformed sections and the non-deformed sections configured to reduce rotation of the collection tube about the outer surface of the drainage conduit to thereby better secure the collection tube to the drainage conduit.

US Pat. No. 10,165,739

APPARATUS AND METHOD FOR CUTTING A ROOT BALL

356864 Alberta LTD., Air...

1. An apparatus for forming a root ball comprising:(a) a frame that is operatively couplable to a support vehicle;
(b) at least one arm that is connected to the frame comprising:
(i) a first tower that is supported by the at least one arm;
(ii) a first cutting-member that is supported by the first tower and movable between a retracted position and an extended position along a substantially linear-path;
(iii) a second tower that is supported by the at least one arm; and
(iv) a second cutting-member that is supported by the second tower and moveable between a retracted position and an extended position along an arcuate path, wherein in operation the second cutting-member moves along the arcuate path to cut a lower wall of a root ball;wherein the first cutting-member and the second cutting-member are movable from their retracted to extended positions independently of each other.

US Pat. No. 10,165,736

AUTONOMOUS MOBILE PLATFORM AND VARIABLE RATE IRRIGATION METHOD FOR PREVENTING FROST DAMAGE

International Business Ma...

1. A method for dispensing water for crops to protect plant life from frost damage, comprising:traversing a field with a self-propelled rover, the rover including a tower coupled to a base and extending over the base and a plurality of sensors set on the tower and the base, the tower and base configured to sense weather conditions around the rover concurrently at different elevations relative to the base and at different locations in the field;
measuring the weather conditions at the different elevations and at the different locations in the field using the plurality of sensors on the rover;
evaluating local measurement data to determine an amount and manner for disbursement of water under the weather conditions for the different elevations and at the different locations in the field; and
delivering the water until goal conditions are met.

US Pat. No. 10,165,735

DYNAMIC PLANT LIGHTING SYSTEMS AND METHODS

Full Spectrum Industries ...

1. A dynamically engaged cannabis plant stimulation lighting system comprising:at least one light emitting diode capable of providing at least four emission spectra to cannabis plants, said emission spectra comprising:
at least one ultra violet wavelength between about 420 and about 425 nm;
at least one blue wavelength at about 460 nm;
at least one red wavelength at about 660 nm; and
at least one infrared wavelength between about 720 nm and about 740 nm;
wherein said at least one light emitting diode is capable of providing a color temperature between about 3500K and about 5000K to said cannabis plants;
wherein said at least one light emitting diode is capable of providing a color rendering index between about 70 and about 100 to said cannabis plants; and
a variable output intensity control capable of varying each of said four emission spectra output intensity; and
an event time for each of said emission spectra, wherein said event time for said infrared wavelength between about 720 and about 740 nm is about 15 minutes at the beginning and at the end of a light cycle.

US Pat. No. 10,165,733

URN AND PLANTER COMBINATION

1. A container that holds both of ashes resulting from cremation of a decedent and a living plant or bonsai tree comprising:a first compartment for containing the living plant with soil;
at least one additional compartment in which at least a portion of the ashes of the decedent and soil co-mingle; and
a plurality of openings communicating between said first compartment and said at least one additional compartment and providing a pathway for plant roots to migrate between the first and the at least one additional compartment;
wherein at least some of the ashes from the decedent are incorporated into the living plant.

US Pat. No. 10,165,732

AERIAL FLUID APPLICATION TECHNOLOGY FOR ORCHARDS, VINEYARDS AND THE LIKE

1. A device for delivering a gas to an individual plant, comprising: an elongated, straight, vertical base adapted to be placed on a ground a predetermined distance from the individual plant and upwind from the individual plant, an emitter assembly adjustably disposed on the base, a gas supply conduit communicatively connected to the emitter assembly and adapted to be connected to a gas supply, and a vertically disposed wind foil, the wind foil having an upwind first face and a downwind second face, the emitter assembly being disposed on the second face of the wind foil towards the individual plant, whereby in use, as emitted from the emitter assembly away from the second face of the wind foil forms a gas envelope proximate at least a portion of the individual plant, and whereby the wind foil shields the gas envelope from wind so that it remains proximate at least a portion of the individual plant.

US Pat. No. 10,165,731

MECHANICAL DISCHARGER COMBINED WITH AN EXTRACTOR DEVICE FOR BULK PRODUCT STORED IN SILO-BAGS

1. An apparatus for a mechanical product discharger combined with an extractor device for a product stored in a silo bag with one end longitudinally opened, the product discharger is a continuous conveyor structure with a lower loading part substantially horizontally and transversely positioned within the silo bag, and an upper loading part inclined with respect to the ground with a top discharge end in the cargo box of a loading vehicle, said apparatus comprises:an upper winding tube;
a lower winding tube positioned below said upper winding tube so that a separation space is provided between both winding tubes; and
a tension element coupled to said lower winding tube to maintain said separation space and prevent contact between both winding tubes, said lower winding tube being configured to support, secure and draw a lower part of a silo bag and said upper winding tube being configured to support, secure and draw an upper part of said silo bag so that said lower part and said upper part are synchronously wound over said lower winding tube and said upper winding tube, respectively, when said upper and lower winding tubes are rotated.

US Pat. No. 10,165,730

METHOD OF OPERATING AN AGRICULTURAL BALER

CNH Industrial America LL...

1. A method of operating an agricultural baler, comprising the steps of:measuring with a sensor at least one physical input parameter associated with a compression profile of crop material in a bale chamber of the baler, wherein a plunger is configured for reciprocation within the bale chamber for compressing the crop material;
analyzing the compression profile of the crop material with a controller, dependent upon the measured at least one physical input parameter; and
adjusting at least one physical output parameter of the baler using a controller which affects the compression profile of the crop material in the bale chamber;
wherein analyzing the compression profile comprises:
performing a compression analysis and a relaxation analysis of the crop material within the bale chamber during bale formation.

US Pat. No. 10,165,729

SHAKER HEAD AND RELATED METHODS

1. A shaker mechanism for use in a tree shaker having a mobile frame and means for engaging a tree, comprising:a. two bilaterally positioned eccentric weights symmetrically positioned with respect to a central axis of a shaker head on a same plane of rotation, wherein said bilaterally positioned eccentric weights are operable to rotate at the same angular velocity during operation, and centers of mass of said two laterally positioned eccentric weights are in phase in a first instance and a second instance during each 360° rotation of the two laterally positioned eccentric weights, said centers of mass of said two bilaterally positioned eccentric weights being in phase in said first instance in alignment along a line that is perpendicular to the central axis of the shaker head such that said centers of mass are at their closest point to a first lateral side of said shaker head, and said centers of mass of said two bilaterally positioned eccentric weights being in phase in said second instance along said line that is perpendicular to the central axis of the shaker head such that said centers of mass are at their closest point to a second lateral side of said shaker head;
b. at least one central sprocket wheel located on said central axis of said shaker head;
c. a motor for driving the rotation of said bilaterally positioned eccentric weights; and
d. at least one drive chain or belt operable to engage with sprockets on rotational shafts of said bilaterally positioned eccentric weights.

US Pat. No. 10,165,727

TRIMMER HEAD

TECOMEC S.R.L., Reggio E...

1. A trimmer head comprising:a casing designed to be coupled to a driveshaft for rotating about a main axis, the casing comprising an upper shell and a lower shell, the lower shell comprising a second toothing that protrudes upwardly and a track that is oriented radially with respect to the main axis;
an upper disk secured to the upper shell;
a lower disk comprising a first toothing that protrudes downwardly;
at least one spool of cutting wire between the lower disk and the upper disk;
a spring disposed between the upper shell and the upper disk; and
a mass disposed between the lower shell and the lower disk configured to move in a radial direction within the track with respect to the main axis
wherein in an engagement position, the spring urges the upper disk and the lower disk towards the lower shell, such that the first toothing and the second toothing are engaged and the upper disk and lower disk rotate with the lower shell,
wherein in a free position, the mass moves in the track radially away from the main axis to push the lower disk away from the lower shell and disengage the first toothing and the second toothing such that the upper disk and lower disk rotate with respect to the lower shell,
wherein the lower disk and the upper disk are independent of one another and are within the lower shell.

US Pat. No. 10,165,725

CONTROLLING GROUND ENGAGING ELEMENTS BASED ON IMAGES

1. A mobile machine comprising:map generator logic configured to receive a first data set and a second data set, wherein the first and second data sets comprise indications of a soil parameter of a worksite, wherein the soil parameter comprises soil temperature, and wherein the first data set is captured at an earlier time than the second data set and, based on the first and second data sets, generate a soil temperature map of the worksite;
a controllable subsystem;
a controller configured to generate a control signal based on both a position of the agricultural machine within the worksite and the generated soil temperature map; and
a control system configured to control the controllable subsystem based on the control signal.

US Pat. No. 10,165,722

SCOUTING SYSTEMS

1. An agricultural scouting system comprising:a ground vehicle having a perception sensor, a motion sensor and a computer, wherein the ground vehicle is autonomous;
wherein the computer receives motion information from the motion sensor as the ground vehicle moves;
wherein the computer having instructions to ascertain from the perception sensor a position of the ground vehicle in a coordinate system of the ground vehicle, forming an occupancy grid based on a strength associated with cells of the occupancy grid; and the computer to transform the coordinate system to a second coordinate system;
wherein the second coordinate system includes a global motion of the ground vehicle and surrounding objects to generate candidate crop lanes, and wherein generating the candidate crop lanes includes identifying and classifying one or more non-crop plant in-lier objects arranged within the candidate crop lanes; a row model, wherein the candidate crop lanes are compared to the row model; and a vehicle path that the ground vehicle drives, wherein the vehicle path is based on a best scorer among the candidate crop lanes; and
wherein the computer is configured to generate an output signal received by an external vehicle to cause the external vehicle to perform a task when the one or more non-crop plant in-lier objects are identified within the candidate crop lanes.

US Pat. No. 10,165,721

DISC HOLDER AND SCRAPER CONSTRUCTION FOR DISC HARROWS

BIANCHI S.R.L., Piadena ...

1. A disc holder and scraper construction (1) for disc harrows, characterized in that said disc holder and scraper construction (1) comprises a disc element (2) affixed to a rotary hub (3), supported by a disc holder spring (4) to which is affixed a flexible disc scraper arm (8), made of spring steel, at a hot molded recess (10) on said disc scraper arm (8) made of spring steel, where said recess (10) engages said disc holder spring (4) at a point adjacent to a point of attachment of said rotary hub (3) to said disc holder spring (4), wherein said hot molded recess (10) prevents said flexible disc scraper arm (8) made of spring steel from being laterally offset and; wherein said disc holder spring (4) is in turn affixed to a framework (5) of a disc harrow, said disc holder spring (4) and said disc scraper arm (8)made of spring steel, being mounted on a convex side of said disc element (2), said disc holder and scraper construction (1) being adapted to remove soil adhering to said disc element (2) by a scraper assembly (7) affixed to said flexible disc scraper arm (8) made of spring steel so that said scraper assembly (7) will move when said flexible scraper arm (8) made of spring steel moves.
US Pat. No. 10,166,604

COMPOSITION OF PARTICULATE MATERIALS AND PROCESS FOR OBTAINING SELF-LUBRICATING SINTERED PRODUCTS

Whirlpool, S.A., Sao Pau...

1. A metallurgical composition of particulate materials, for forming conformed and sintered self-lubricating composite products, comprising:a main particulate metallic material, in the form of a main chemical element, wherein the main particulate metallic material is iron, and at least one particulate hardening element, which form a structural matrix in the composite product to be sintered wherein the particulate hardening element has the function of hardening the structural matrix;
a non-metallic particulate solid lubricant, at least partially soluble in the structural matrix, wherein the particulate solid lubricant is a mixture consisting of graphite and hexagonal boron nitride;
an alloy component, with the function of stabilizing the iron alpha phase and of preventing the solubilization of the particulate solid lubricant in the iron; and
at least one particulate alloy element capable of forming, during a sintering of a conformed metallurgical composition, a liquid phase between the main particulate metallic material which forms the structural matrix and the particulate solid lubricant, agglomerating the latter in discrete particles;
wherein the particulate solid lubricant represents a volumetric percentage lower than or equal to 15% of the volume of the composite material to be formed and the particulate hardening element, the particulate alloy element and the alloy component are silicon, at contents from 2% to 5% by weight of the metallurgical composition; and wherein said composition being conformed by compaction and characterized in that the main particulate metallic material of iron presents an average particle size lying between about 10 ?m and about 90 ?m, the hardening element with the function of hardening the structural matrix, and the particulate alloy element with the function of forming the liquid phase and agglomerating the particulate solid lubricant, during the sintering of the metallurgical composition conformed by compaction, presenting an average particle size smaller than about 45 ?m.
US Pat. No. 10,167,375

RUBBER COMPOSITION, CROSSLINKED RUBBER COMPOSITION, AND TIRE

BRIDGESTONE CORPORATION, ...

1. A rubber composition comprising carbon black, wherein62.5×24M4DBP+hydrogen amount of carbon black?8337.5  (1)
24M4DBP?0.25×CTAB?62.5  (2)
Dst+0.75×?D50?152.5  (3)
0.885??D50/Dst?1.030  (4)
where 24M4DBP indicates a compressed-sample DBP absorption number (cm3/100 g), CTAB indicates a CTAB adsorption specific surface area (m2/g), Dst indicates a highest frequency value (nm) on a Stokes' diameter distribution curve, ?D50 indicates a full width at half maximum (nm) of the distribution curve with respect to Dst, and the hydrogen amount of carbon black is in units of mass ppm.
US Pat. No. 10,167,378

PROCESSING DEVICE AND PROCESSING METHOD OF FIBER CONTAINING RESIN

TOYOTA JIDOSHA KABUSHIKI ...

1. A processing method of a fiber containing resin, comprising:placing a fiber containing resin in a dry distillation-carbonization chamber, wherein the fiber containing resin contains fibers and a matrix resin;
sealing the dry distillation-carbonization chamber to shut air off;
heating the fiber containing resin in the absence of oxygen to thermally decompose and carbonize the matrix resin in the fiber containing resin to obtain a bundle of fibers;
immersing the resulting bundle of fibers in a solvent held in a container; and
stirring the resulting bundle of fibers to disentangle the fibers.
US Pat. No. 10,167,379

HYBRID FIBER LAYUP AND FIBER-REINFORCED POLYMERIC COMPOSITES PRODUCED THEREFROM

Cornerstone Research Grou...

9. The method of claim 1 wherein the dry fiber strips, the impregnated fiber strips, or both comprise one or more components selected from the group consisting of carbon fiber, glass fiber, aramid fiber, boron fiber, basalt fiber, ceramic fiber, quartz fiber, alumina fiber, and polymer fiber.
US Pat. No. 10,167,380

COMPOSITE MATERIAL

FiberSpec LLC, Two River...

1. A composite material, comprising:a plurality of beads, each bead having a diameter of at least 0.05 mm;
a plurality of fibers, each fiber having a length and a width; and
a resin binder;
wherein, the length of each fiber is greater than the width of each fiber; and
wherein the width of each fiber is less than the diameter of each bead.
US Pat. No. 10,167,124

SHAVE CREAM POD

PACIFIC SHAVING COMPANY, ...

1. A shaving cream formulation comprising:one or more surfactants, present in the amount of over fifty (50) percent by weight, based on a total weight of the formulation, wherein at least one of the one or more surfactants is selected from the group consisting of triethanolamine myristate and triethanolamine stearate, and is present in an amount of over fifteen (15) percent by weight based on a total weight of the formulation;
one or more emulsifying agents, present in the amount of from about five (5) to about forty (40) percent by weight, based on the total weight of the formulation; and
water,wherein water is present in an amount of from about one (1) weight percent to about fifteen (15) weight percent, based on the total weight of the formulation.
US Pat. No. 10,167,381

LIGHTWEIGHT WALL REPAIR COMPOUNDS

3M Innovative Properties ...

1. A wall repair compound, comprising,from about 20 percent to about 80 percent by weight aqueous latex binder emulsion that comprises an acrylic binder with a glass transition temperature from about 15° C. to about 35° C.;
from about 20 percent to about 70 percent by weight of an inorganic filler system that comprises substantially spherical synthetic particles that are glass bubbles; and,
reinforcing fibers.
US Pat. No. 10,167,383

PROCESS TO FORM ETHYLENE/ALPHA-OLEFIN INTERPOLYMERS

Dow Global Technologies L...

1. A process to form a “first composition comprising a first ethylene/?-olefin interpolymer and a second ethylene/?-olefin interpolymer,”said process comprising polymerizing via solution polymerization a first mixture comprising ethylene, an ?-olefin, and optionally a polyene, in a continuous stirred tank reactor to form a first ethylene/?-olefin interpolymer, and
transferring at least some of the first ethylene/?-olefin interpolymer to a loop reactor, and polymerizing via solution polymerization, therein, a second mixture comprising ethylene, an alpha-olefin, and optionally a polyene, in the presence of the first ethylene/?-olefin interpolymer, to form the “first composition comprising the first ethylene/?-olefin interpolymer and the second ethylene/?-olefin interpolymer”,
wherein the ratio of “the solution viscosity of the first ethylene/?-olefin interpolymer, in the stirred tank reactor, at the stirred tank reactor temperature” to “the solution viscosity of the first composition, in the loop reactor, at the loop reactor temperature” is greater than, or equal to, 3.0.
US Pat. No. 10,167,384

COMPOSITION COMPRISING HETEROPHASIC PROPYLENE COPOLYMER

SABIC GLOBAL TECHNOLOGIES...

1. A composition comprising:(A) a heterophasic propylene copolymer,
(B) talc and
(C) a functionalized polypropylene grafted with an acid or acid anhydride functional group, wherein the heterophasic propylene copolymer consists of
(a) a propylene-based matrix, wherein the propylene-based matrix consists of a propylene homopolymer and/or a propylene-?-olefin copolymer consisting of at least 70 wt % of propylene and at most 30 wt % of ?-olefin, based on the total weight of the propylene-based matrix and
wherein the propylene-based matrix is present in an amount of 90 to 95 wt % based on the total heterophasic propylene copolymer and
(b) a dispersed ethylene-?-olefin copolymer, wherein the dispersed ethylene-?-olefin copolymer is present in an amount of 10 to 5 wt % based on the total heterophasic propylene copolymer and
wherein the sum of the total amount of propylene-based matrix and total amount of the dispersed ethylene-?-olefin copolymer in the heterophasic propylene copolymer is 100 wt %,
wherein the heterophasic propylene copolymer has an MFI of 0.1-0.5 dg/min as determined according to ISO1133 at 230° C. and 2.16 kg and
wherein the amount of the talc in the composition is 0.025-10 wt % of the total composition and the amount of the functionalized polypropylene is 0.005-2.5 wt % of the total composition.
US Pat. No. 10,167,393

POLY(VINYL ACETATE) DISPERSION, AND A PAINT FORMULATION COMPRISING THEREOF

Dow Global Technologies L...

1. A polymer dispersion comprising by dry weight based on total dry weight of the polymer particles, a) from 60% to 95% a vinyl acetate monomer, b) from 0.2% to 2.5% a phosphorus-containing allylic monomer; and c) from 0.2% to 2.5% an itaconic acid monomer; wherein the total amount of monomers b) and c) is from 0.5% to 2.5% by dry weight based on total dry weight of the polymer particles, and the dry weight ratio of monomer b) to monomers b) and c) is from 0.2 to 0.6,wherein the phosphorus-containing allylic monomer is a monomer of formula (I) [CH2?CH—CH2—R2—O-]xP(?O)(OM)3-x,
wherein R2 is a linking divalent group, x is an average number of from 1 to 2, and M is a hydrogen atom or a cationic counter-ion.
US Pat. No. 10,167,399

INK, INK CARTRIDGE, AND IMAGE RECORDING METHOD

Canon Kabushiki Kaisha, ...

1. An ink comprising:a pigment;
resin particles;
a water-soluble organic solvent; and
water,
wherein a solid content, containing at least the pigment, of a first liquid, as prepared by (i) diluting the ink 500-fold with water on a mass basis, and (ii) adding CaCl2 so as to bring a concentration of the CaCl2 in the first liquid to 1.5 mM, has a rate of aggregation at 25° C. of 1.5 nm/second or less,
wherein a solid content, containing at least the pigment, of a second liquid, as prepared, after the ink has been stored at 60° C. for 2 weeks, by (i) diluting the ink 500-fold with water on a mass basis, and (ii) adding CaCl2 so as to bring a concentration of the CaCl2 in the second liquid to 5 mM, has a rate of aggregation at 25° C. of 2.0 nm/second or more,
wherein the resin particles are acrylic resin particles or polyurethane resin particles, and
wherein the acrylic resin constituting the acrylic resin particles is a homopolymer or copolymer of one or more (meth)acrylic monomers.
US Pat. No. 10,166,120

ORTHOPEDIC DEVICE AND POLYMER COMPOSITIONS FOR MAKING SAME

Ticona LLC, Florence, KY...

1. A polymer composition comprising:a polyoxymethylene polymer, the polyoxymethylene polymer having a melt volume flow rate of less than 15 cm3/10 min when tested at 190° C. under a load of 2.16 kg, the polyoxymethylene polymer being present in the polymer composition in an amount of at least 70% by weight; and
a copolyamide and a dicyandiamide blended with the polyoxymethylene polymer, the copolyamide and the dicyandiamide being present in the composition at a weight ratio of greater than 2:1.
US Pat. No. 10,170,735

BATTERY PACK

SAMSUNG SDI CO., LTD., Y...

1. A battery pack, comprising:a plurality of batteries arranged in columns and rows;
a first holder to accommodate upper parts of the plurality of batteries, the first holder including consecutively arranged external concave surfaces and external convex surfaces and a first pin on the external concave surfaces of the first holder, the external concave surfaces of the first holder being between lateral sides of adjacent batteries of the plurality of batteries; and
a second holder to accommodate lower parts of the plurality of batteries, the second holder including consecutively arranged external concave surfaces and external convex surfaces, the external concave surfaces of the second holder being between the lateral sides of the adjacent batteries of the plurality of batteries, wherein
the first pin of the first holder protrudes toward the second holder to connect to the external concave surfaces of the second holder, and is interlocked with the external concave surfaces of the second holder.
US Pat. No. 10,167,406

WHITE PIGMENT DISPERSIONS

Hewlett-Packard Developme...

1. A white pigment dispersion, comprising:an aqueous liquid vehicle; and
from 5 wt % to 70 wt % of a white metal oxide pigment dispersed by two co-dispersants, wherein the metal oxide pigment has an average particulate size from 100 nm to 1 ?m, and wherein the co-dispersants include both i) a short-chain anionic dispersant having a weight average molecular weight ranging from 1,000 Mw to 30,000 Mw, and ii) a non-ionic or predominantly non-ionic dispersant.
US Pat. No. 10,167,407

AQUEOUS POLYMER DISPERSION FOR PAPER WITH A COPOLYMER OF VINYL ACETATE AND AN ACRYLATE MONOMER PREPARED IN THE PRESENCE OF A STARCH DERIVATIVE

BASF SE, Ludwigshafen (D...

1. A process for preparing an aqueous dispersion comprising a polymer P, the process comprising:emulsifying a mixture comprising monomers in an aqueous medium, and
polymerizing the monomers in the presence of a free-radical initiator and a starch derivative,
wherein the mixture consists of:
vinyl acetate, as a monomer (a),
at least one acrylate monomer, which is at least one selected from the group consisting of a C1-C10 alkyl acrylate and a C1-C10 alkyl methacrylate, as a monomer (b),
at least one ?,?-ethylenically unsaturated C3-C6 carboxylic acid, as a monomer (c),
at least one monomer selected from the group consisting of glycidyl methacrylate, glycidyl acrylate, allyl methacrylate and allyl acrylate, as a monomer (d),
optionally at least one ethylenically unsaturated sulfonic acid, as a monomer (e), and
optionally at least one ethylenically unsaturated other monomer, which is
different from the monomers (a), (b), (c), (d) and (e), as a monomer (f), and wherein
the content of the vinyl acetate monomer (a) is from 70 to 94.7 parts by weight of the monomers,
the content of the at least one acrylate monomer (b) is from 5 to 25 parts by weight of the monomers,
the content of the at least one ?,?-ethylenically unsaturated C3-C6 carboxylic acid monomer (c) is from 0.1 to 10 parts by weight of the monomers,
the content of the at least one monomer (d) selected from the group consisting of glycidyl methacrylate, glycidyl acrylate, allyl methacrylate and allyl acrylate is from 0.1 to 10 parts by weight of the monomers,
the optional content of the at least one ethylenically unsaturated sulfonic acid monomer (e) is from 0.1 to 5 parts by weight of the monomers,
the optional content of the at least one other ethylenically unsaturated monomer (f) is from 0.1 to 15 parts by weight of the monomers, and
the sum total of the parts by weight of the monomers (a), (b), (c), (d), (e) and (f) is 100.
US Pat. No. 10,167,408

AQUEOUS COMPOSITION WITH IMPROVED ELONGATION AT BREAK

DSM IP ASSETS B.V., Heer...

1. An aqueous polymer composition comprising(i) 5 to 30 wt. % of polyurethane obtained by the reaction of:
(a)
(1) 9 to 31 wt. % of at least one polyisocyanate;
(2) 0 to 8 wt. % of at least one isocyanate-reactive compound with a weight average molecular weight in the range of from 50 to 500 g/mol, containing ionic or potentially ionic water-dispersing groups;
(3) 0 to 91 wt. % of at least one isocyanate-reactive compound with a weight average molecular weight in the range of from 501 to 5000 g/mol containing ionic or potentially ionic water-dispersing groups;
(4) 0 to 91 wt. % of at least one isocyanate-reactive compound with a weight average molecular weight in the range of from 501 to 5000 g/mol not comprised by (3);
where (3) and (4) add up to 57 to 91 wt. %;
(5) 0 to 10 wt. % of at least one isocyanate-reactive compound with a weight average molecular weight in the range of from 50 to 500 g/mol not comprised by (2);
where (1), (2), (3), (4) and (5) add up to 100%; and
(b) at least one chain-extending compound;
where the acid value of the resulting polyurethane (i) is between 3 to 40 mg KOH/g;
(ii) 70 to 95 wt. % of vinyl polymer comprising
(c) 20 to 90 wt. % of vinyl polymer with Tg<20° C.;
(d) 10 to 80 wt. % of vinyl polymer with Tg?20° C.;
wherein (c) and (d) add up to 100%;
where at least one of (c) and (d) contains acid functional groups with an acid value in the range of from 15 to 240 mg KOH/g; and
wherein (i) and (ii) add up to 100%.
US Pat. No. 10,167,413

ICE-PHOBIC COATING FORMULATIONS AND USES THEREOF

Ames Rubber Corporation, ...

15. A ice-phobic coating formulation comprising:an elastomer comprising silicone;
filler particles comprising silica nanoparticles, wherein the silica nanoparticles are present at a weight percent in the formulation ranging from 1 wt % to 5 wt %; and
a cryoprotectant comprising one or more of trehalose, dimethylsulfoxide (DMSO), or polyvinyl alcohol (PVA), wherein the cryoprotectant is present at a weight percent in the formulation ranging from 1 wt % to 3 wt %,
wherein the ice-phobic coating formulation is adapted to form an ice-phobic coating having an ice adhesion failure stress ranging from 1 kPa to 20 kPa,
wherein the formulation is a solventless curable coating formulation.
US Pat. No. 10,167,416

HIGH PERFORMANCE WATER-BASED ADHESION COMPOSITIONS AND APPLICATIONS

HONEYWELL INTERNATIONAL I...

1. An adhesion composition comprising:(a) a first polymer, having a number average molecular weight greater than about 50,000 Daltons but not greater than about 100,000 Daltons, and chosen from acrylic polymers comprising a majority component of either 2-ethylhexylacrylate or butyl acrylate copolymerized with a minority component of either methyl methacrylate, vinyl acetate, or styrene;
(b) a second polymer different than said first polymer, having a number average molecular weight less than about 20,000 Daltons, and consisting of ethylene-acrylic acid copolymers in combination with an oxidized polyethylene polymer;
(c) surfactant in an amount of about 0.05% to about 0.5%; and
(d) water, where the amount of said water, said first polymer and said second polymer is sufficient to provide the composition with a solids content of greater than about 30% based on the total weight of components (a)-(d) in the adhesion composition and where said first polymer and said second polymer comprise solid particles having a D50 particle size of from about 10 nanometers (nm) to about 2000 nm.
US Pat. No. 10,170,749

ALKALI METAL BATTERY HAVING AN INTEGRAL 3D GRAPHENE-CARBON-METAL HYBRID FOAM-BASED ELECTRODE

Nanotek Instruments, Inc....

1. An alkali metal battery having an anode, a cathode, an electrolyte in ionic contact with said anode and said cathode, and an optional porous separator electronically separating said anode and said cathode, wherein said anode comprises an integral 3D graphene-carbon-metal hybrid foam comprised of multiple pores, pore walls, and a lithium-attracting metal or sodium-attracting metal residing in said pores or deposited on said pore walls; wherein said lithium-attracting metal is selected from the group consisting of Au, Ag, Mg, Zn, Ti, Na, K, Al, Fe, Mn, Co, Ni, Sn, V, Cr, and an alloy thereof for a lithium metal battery, or said sodium-attracting metal is selected from the group consisting of Au, Ag, Mg, Zn, Ti, Li, K, Al, Fe, Mn, Co, Ni, Sn, V, Cr, and an alloy thereof for a sodium metal battery, and is in an amount of 0.1% to 90% of the total hybrid foam weight, and said pore walls comprise single-layer or few-layer graphene sheets chemically bonded by a carbon material having a carbon material-to-graphene weight ratio from 1/200 to 1/2, wherein said few-layer graphene sheets have 2-10 layers of stacked graphene planes having an inter-plane spacing d002 from 0.3354 nm to 0.40 nm as measured by X-ray diffraction and said single-layer or few-layer graphene sheets comprise a pristine graphene material having essentially zero % of non-carbon elements, or a non-pristine graphene material having 0.001% to 25% by weight of non-carbon elements wherein said non-pristine graphene is selected from graphene oxide, reduced graphene oxide, graphene fluoride, graphene chloride, graphene bromide, graphene iodide, hydrogenated graphene, nitrogenated graphene, doped graphene, chemically functionalized graphene, or a combination thereof; wherein said integral 3D graphene-carbon-metal hybrid foam is pre-loaded with lithium or sodium before said battery is made, or said anode further comprises a lithium source or a sodium source.
US Pat. No. 10,167,418

HOT MELT SILICONE AND CURABLE HOT MELT COMPOSITION

Dow Corning Co., Ltd., T...

1. A curable hot melt composition comprising: (I) a hot melt silicone; (II) an organopolysiloxane which has at least two silicon atom-bonded hydrogen atoms in a molecule and in which an amount of silicon atom-bonded hydrogen atom is 0.5 mass % or greater, in an amount such that an amount of the silicon atom-bonded hydrogen atom in component (II) is from 0.5 to 2.0 mol per 1 mol of alkenyl group in component (I); and (III) a hydrosilylation reaction catalyst,wherein component (I) is non-flowable at 25° C. and has a melt viscosity at 100° C. of 5,000 Pa·s or less, and is formed by subjecting (A) an alkenyl group-containing organopolysiloxane in which 10 mol % or greater of all of silicon atom-bonded organic groups is a phenyl group, and (B) an organopolysiloxane having at least two silicon atom-bonded hydrogen atoms in a molecule, in an amount such that an amount of the silicon atom-bonded hydrogen atoms in component (B) is from 0.2 to 0.7 mol per 1 mol of alkenyl group in component (A), to hydrosilylation reaction in the presence of (C) a hydrosilylation reaction catalyst, in an amount that is sufficient to promote the hydrosilylation reaction of components (A) and (B).
US Pat. No. 10,170,752

METHOD FOR PRODUCING AMORPHOUS CARBON PARTICLE, AMORPHOUS CARBON PARTICLES, NEGATIVE ELECTRODE MATERIAL FOR LITHIUM ION SECONDARY BATTERIES, AND LITHIUM ION SECONDARY BATTERY

JFE CHEMICAL CORPORATION,...

1. A method for producing amorphous carbon particles, the method comprising:(a) (i) obtaining a first crosslinked product by first mixing mesophase particles with an amorphous carbon precursor and then subjecting the mixture to a crosslinking treatment including an air blowing reaction performed in a liquid phase reaction at a temperature in a range of 280 to 420° C., or (ii) obtaining a second crosslinked product by first crosslinking the amorphous carbon precursor and then mixing the mesophase particles with the crosslinked precursor; and
(b) subjecting the first or second crosslinked product to an infusibilization treatment performed in a solid phase using an oxidizing gas to form an infusibilized product having an oxygen content in a range of 3 to 20 mass % and then firing the infusibilization product to produce amorphous carbon particles, such that the mesophase particles are within the amorphous carbon particles,
wherein crushing is performed at least one of before and after the infusibilization treatment.
US Pat. No. 10,170,754

SILICON MONOXIDE COMPOSITE NEGATIVE ELECTRODE MATERIAL USED FOR LITHIUM ION BATTERY, THE PREPARATION METHOD THEREOF AND A LITHIUM ION BATTERY

Shenzhen BTR New Energy M...

1. A silicon monoxide composite negative electrode material, which comprises, from inside to outside, a silicon monoxide substrate, a carbon material coating layer on the surface of the substrate, a crystalline nano-silicon material uniformly deposited on the carbon material coating layer and a nanoscale conductive material coating layer on the surface of the silicon monoxide substrate/carbon material coating layer/crystalline nano-silicon material, wherein the crystalline nano-silicon material is mono-dispersed nano-silicon particles with an average particle size of 1.0-1000.0 nm.
US Pat. No. 10,167,424

COLOR-TUNABLE UP-CONVERSION NANOPHOSPHOR

Korea Institute of Scienc...

1. An up-conversion nanophosphor comprising:a core comprising a Yb3+-doped fluoride-based nanoparticle represented by LiY1-x-yLyF4:Yb3+x, where, x and y are real numbers, and 0?x?1, 0?y?1, and 0?x+y?1, and L is any one selected from Y, Dy, Ho, Er, Tm, Lu, and a combination thereof;a first shell comprising a fluoride-based crystalline compound that is co-doped with at least one selected from Yb3+ and Tm3+, the fluoride-based crystalline compound surrounding at least a portion of the core, and represented by LiGd1-p-q-rMrF4:Yb3+p,Tm3+q, where, p, q and r are real numbers, and 0
US Pat. No. 10,170,757

NEGATIVE ELECTRODE MATERIAL FOR LITHIUM ION SECONDARY BATTERY, NEGATIVE ELECTRODE, AND LITHIUM ION SECONDARY BATTERY

SHIN-ETSU CHEMICAL CO., L...

1. A negative electrode material for use in a lithium ion secondary battery, comprising silicon-containing particles which are capable of intercalating and deintercalating lithium ions and are characterized by having a volume base particle size distribution, as measured with a laser diffraction-type particle size analyzer, whereinD50 is from 0.5 to 10 ?m,
D90 is from 5 to 15 ?m,
(modal diameter—D50)/D50=0.15 to 0.50 and
(D90—modal diameter)/D90=0.05 to 0.20, wherein
D50 is the cumulative 50% diameter, and
D90 is the cumulative 90% diameter.
US Pat. No. 10,170,760

LITHIUM ION SECONDARY BATTERY

SK Innovation CO., LTD., ...

1. A secondary battery comprising:A cathode active material in which at least one of metals forming the cathode active material has a concentration gradient in an entire region from a central portion up to a surface portion;
a conductive material mixture in which carbon nanotube is mixed with carbon black; and wherein the carbon black and the carbon nanotube are mixed at a mixing ratio of 10:1 to 6:4,
wherein the cathode active material is represented by Chemical Formula 1 below, and in Chemical Formula 1, at least one of M1, M2, and M3 has a continuous concentration gradient from the central portion up to the surface portion:
LixM1aM2hM3cOv  Chemical Formula 1
wherein in Chemical Formula 1,
M1 is Ni, M2 is Mn, and M3 is Co, and
0 wherein any one of M1, M2, and M3 has a predetermined concentration from the central portion up to the surface portion, and another one has a concentration gradient region in which a concentration is increased from the central portion up to the surface portion, and the other one has a concentration gradient region in which a concentration is decreased from the central portion up to the surface portion,
wherein the central portion of the particle means a portion within a radius of 0.1 to 0.2 ?m from the center of the active material particle, and the surface portion of the particle means a portion within a radius of 0.1 to 0.2 ?m from the outermost of the particle.
US Pat. No. 10,168,453

POLARIZING PLATE PROTECTIVE FILM, POLARIZING PLATE, IMAGE DISPLAY DEVICE, AND METHOD OF MANUFACTURING POLARIZING PLATE PROTECTIVE FILM

FUJIFILM Corporation, To...

1. A polarizing plate protective film comprising a substrate and a hard coat layer,wherein the hard coat layer is a layer formed by curing a photocurable composition containing a polyfunctional (meth)acrylate compound and an acid anhydride,
wherein a content of the acid anhydride in the photocurable composition is 8-20% by mass based on a total solid content of the photocurable composition,
wherein a content of the polyfunctional (meth)acrylate compound in the photocurable composition is 40-88.44% by mass based on the total solid content of the photocurable composition, and
wherein the acid anhydride is contained in the hard coat layer.
US Pat. No. 10,170,763

LITHIUM METAL OXIDE PARTICLES COATED WITH A MIXTURE OF THE ELEMENTS OF THE CORE MATERIAL AND ONE OR MORE METAL OXIDES

Umicore, Brussels (BE)

1. A lithium metal oxide powder for use as a cathode material in a rechargeable battery, comprising a core material and a surface layer,the core material comprising a layered crystal structure comprising the elements Li, a metal M and oxygen, wherein the Li content is stoichiometrically controlled, the metal M has the formula M=Co1-aM?a, with 0?a?0.05, and M? is either one or more metals selected from the group consisting of Al, Ga and B; and
the surface layer having a thickness of at least 50 nm and comprising a mixture of the elements of the core material, Li, M, and oxygen, and inorganic N-based oxides, wherein N is one or more metals selected from the group consisting of Mg, Ti, Fe, Cu, Ca, Ba, Y, Sn, Sb, Na, Zn, Zr and Si, and wherein the concentration in N metals decreases with increasing distance from the surface to the core on a gradient, and wherein the concentration of N metals in the core is not zero.
US Pat. No. 10,170,764

METHOD FOR MANUFACTURING ULTRA SMALL PARTICLE, POSITIVE ELECTRODE ACTIVE MATERIAL OF SECOND BATTERY USING THE METHOD FOR MANUFACTURING ULTRA SMALL PARTICLE AND METHOD FOR MANUFACTURING THE SAME, AND SECONDARY BATTERY USING THE POSITIVE ELECTRODE ACTIVE MA

Semiconductor Energy Labo...

1. A method for manufacturing a particle comprising:forming a material film over a substrate;
forming a first protrusion in the material film;
manufacturing a template including a second hole using the material film including the first protrusion; and
filling the second hole in the template with a gel comprising a first material and a second material, whereby a particle is formed in the second hole;
separating the particle from the template by heating,
wherein a diameter of the particle is greater than or equal to 10 nm and less than or equal to 50 nm.
US Pat. No. 10,167,435

LIQUID COMPOSITIONS FOR MARKING LIQUID HYDROCARBON MOTOR FUELS AND OTHER FUELS, MOTOR FUELS AND OTHER FUELS CONTAINING THEM AND PROCESS FOR DETECTING THE MARKERS

Total Marketing Services,...

1. A process for the qualitative detection of at least one marker in a motor fuel or other liquid hydrocarbon fuel comprising:(a) the at least one marker, chosen from the following aliphatic or cycloaliphatic compounds:
tricyclodecenyl isobutyrate (3a,4,5,6,7,7a-hexahydro-4,7-methano-1 h-inden-5 (or 6) -yl) (CAS 67634-20-2);
tricyclodecenyl propionate (CAS 17511-60-3);
cis-3- hexenyl acetate (CAS 3681-71-8);
ethyl linalool (CAS 10339-55-6);
prenyl acetate (CAS 1191-16-8);
ethyl myristate (CAS 124-06-1);
para-tert-butylcyclohexyl acetate (CAS 32210-23-4);
tricyclodecenyl acetate (4,7-methano-1h-inden-6-ol, 3a,4,5,6,7,7a-hexahydro-) (CAS 5413-60-5);
ethyl caprate(CAS 110-38-3),
the at least one marker having a concentration of from 1 ppm to 20 ppm with regard to the motor fuel or other liquid hydrocarbon fuel;
(b) a solvent or a mixture of solvents; and
(c) one or more functional additives for motor fuels and/or other liquid hydrocarbon fuels, chosen from the detergents, dispersants, combustion improvers, anti-foaming agents, conductivity improvers, anti-corrosion additives, lubricity additives, anti-wear agents and/or friction modifiers, chelating agents and/or sequestrating agents of metals, demulsifiers, low temperature behaviour additives, metal passivators, acidity neutralizers, markers different from the markers; the process comprising the following steps:
analyzing a sample of the motor fuel or other liquid fuel containing the at least one marker by an analytic method; and
then detecting the at least one marker.
US Pat. No. 10,167,442

COMPOSITION FOR CLEANING DISARTICULATED SKELETONS

1. A method of cleaning a disarticulated skeleton, comprising the steps of:placing bones from the skeleton in a tank;
filling the tank with a mixture of water, ammonia and hydrogen peroxide;
soaking the bones in the tank filled with the mixture;
continuously pumping ozone through the mixture in the tank while soaking the bones;
removing the bones from the tank; and
rinsing the bones.
US Pat. No. 10,167,446

METHOD FOR INHIBITING CANCER CELLS AND TREATING DISEASES COMPRISING ADMINISTERING A FORMULA COMPOSITION OF ANTRODIA CINNAMOMEA

CHENG-LIN AGRICULTURAL BI...

1. A method for inhibiting cancer cells and treating hepatitis B, diabetes, high blood pressure and intestinal tract diseases by administering a formula composition of a culture medium for cultivating Antrodia cinnamomea to a patient in need thereof wherein the formula composition comprises:growth basal ingredients including hydroxyhopanone and agarwood powders, wherein the growth basal ingredients are further selected from the group consisting of roots, stems, leaves, fruits, flowers of agarwood, and combinations thereof; and
cultivating basal ingredients, with a percentage of the growth basal ingredients being less than 10% of the formula composition of the culture medium, and with mycelia of Antrodia cinnamomea metabolizing hydroxyhopanone precursors of the agarwood powders during a growth procedure of the mycelia of Antrodia cinnamomea, such that the mycelia of Antrodia cinnamomeahave an increased percentage of triterpenoids after fermentation,
wherein the cultivating basal ingredients are selected from the group consisting of wheat, soybean, and combinations thereof.
US Pat. No. 10,167,448

PHARMACEUTICAL COMPOSITION FOR TREATING CEREBROVASCULAR DISEASES, CONTAINING STEM CELL-DERIVED EXOSOME AS ACTIVE INGREDIENT

Samsung Life Public Welfa...

1. A method for treating a cerebrovascular disease, comprising:administering to a subject having the cerebrovascular disease an effective amount of exosome derived from a stem cell,
wherein the cerebrovascular disease is intraventricular hemorrhage (IVH), and
wherein the stem cell is a mesenchymal stem cell.
US Pat. No. 10,167,193

FERROELECTRIC AGGLOMERATES AND METHODS AND USES RELATED THERETO

Vanderbilt University, N...

1. An agglomerate comprising:(a) a particle having a body, wherein the body comprises antimony and a first atom;
(b) a matrix comprising a halogen and a second atom; and
(c) a surface ligand bound to the particle,
wherein the particle is at least partially embedded in the matrix,
wherein the first atom and the second atom are independently selected from Cd, Se, Pb, S, Fe, O, Au, Ag, Te, In, Sn, Eu, Ti, and Ba; and
wherein the agglomerate is ferroelectric.
US Pat. No. 10,167,450

HUMAN PANCREATIC BETA CELL LINES FOR DIAGNOSTIC OF DIABETES

SARL ENDOCELLS, Paris (F...

1. A method of preparing a homogenous human beta cell population that is not contaminated by non-beta cells and comprises human beta cells or human beta cell tumors, wherein said human beta cells or human beta cell tumors express insulin and PDX-1, form insulinomas and restore normoglycemia in diabetic SCID mice after transplantation, said method comprising the steps of:a) transducing or co-transducing immature human pancreases with
i) a first lentiviral vector expressing SV40 LargeT antigen gene under the control of an insulin promoter and a second lentiviral vector expressing hTert gene under the control of the insulin promoter, or
ii) a lentiviral vector expressing both SV40 LargeT antigen and hTert genes, wherein expression of both SV40 LargeT antigen and hTert genes are under the control of the insulin promoter,
thereby producing transduced immature human pancreas cells,
b) introducing the transduced immature human pancreas cells obtained in step a) into a kidney capsule of a first severe combined immunodeficiency (SCID) mouse,
wherein the introduced transduced immature human pancreas cells develop into insulinoma-like structures comprising insulin-producing beta cells in the SCID mouse,
c) micro-dissecting the insulinoma-like structures obtained in step b), dissociating cells thereof, and optionally transducing said dissociated cells with a lentiviral vector expressing an antibiotic resistance gene under the control of the insulin promoter,
d) sub-transplanting the cells obtained in step c) into a kidney capsule of a second SCID mouse,
e) allowing the sub-transplanted cells in step d) to develop and regenerate insulinoma-like structures, wherein said newly developed insulinoma-like structures are enriched in insulin-producing beta cells,
f) micro-dissecting insulinoma-like structures obtained in step e), dissociating and collecting the cells thereof,
g) optionally, sub-transplanting the cells obtained in step f) into a kidney capsule of a third SCID mouse, allowing further enrichment and amplification of insulin producing beta cells,
and optionally repeating steps e), f), and g) until insulin-producing beta cells are produced,
wherein the sub-transplanting step d), and optionally of step g) lead to a homogenous human beta cell population not contaminated by non-beta cells, and wherein the human beta cells express insulin and PDX-1, form insulinomas and restore normoglycemia in diabetic SCID mice after transplantation.
US Pat. No. 10,167,452

VIRAL PURIFICATION METHODS

Oncolytics Biotech Inc., ...

1. A method of producing reovirus from a culture of cells, comprising the steps of:(a) providing a culture of cells which has been infected by the reovirus in culture;
(b) extracting the reovirus from the culture of cells by adding a detergent to the culture of cells and incubating for a period of time to result in a cell lysate;
(c) separating cell debris from the reovirus in the cell lysate; and
(d) collecting the reovirus,provided that after infection by the reovirus and before extraction of the reovirus, the cells are not pelleted or resuspended.
US Pat. No. 10,166,173

POLYURETHANE MICROPARTICLES COATED WITH A ZINC SALT AND METHODS FOR THE PREPARATION THEREOF

Dow Global Technologies L...

1. A composition comprising polyurethane microparticles coated with zinc salt particles, wherein the ratio of zinc salt to polyurethane is in a range of from 1:99 to 3:7, and the polyurethane microparticles have an average particle size of less than 100 microns, wherein the zinc salt comprises zinc pyrithione having an average particle size of less than 2 microns.
US Pat. No. 10,166,174

WET WIPES FOR PERSONAL CARE

KIMBERLY-CLARK WORLDWIDE,...

1. A wet wipe comprising:a porous sheet comprising a coherent web of fibers;
a cleaning composition contained within said porous sheet, said cleaning composition contained within said porous sheet in an amount between 50% and 600% based upon the dry weight of said porous sheet;
said cleaning composition comprising, based upon the weight of the cleaning composition, (i) greater than 92.0% water, (ii) between 4% and 0.05% surfactant, and (iii) between about 3.0% and about 0.05% water insoluble polysaccharide particles and wherein said particles reside on the surface of the fibers of said porous sheet.
US Pat. No. 10,167,199

METHOD FOR MANUFACTURING HIGHLY PURE SILICON, HIGHLY PURE SILICON OBTAINED BY THIS METHOD, AND SILICON RAW MATERIAL FOR MANUFACTURING HIGHLY PURE SILICON

Silicio Ferrosolar S.L., ...

1. A method for producing high purity silicon characterised in that it is a method of high purity silicon production that produces high purity silicon by unidirectional solidification of raw material molten silicon in a molding vessel, and uses as said raw material molten silicon that has a carbon concentration of 100˜1000 ppmw, and a germanium concentration of 50-1000 ppmw wherein a heat extraction process drives said unidirectional solidification forward, a preservation process is provided to preserve the molten state of the molten silicon in the molding vessel and by this preservation process, a silicon carbide contact layer of 20 ?m thickness or more is formed on the surface of the inner wall of the molding vessel.
US Pat. No. 10,167,456

BIFUNCTIONAL LIPASE MUTANT AND METHODS OF USING SAME

JIANGNAN UNIVERSITY, Wux...

1. A method of processing flour products with a lipase mutant,wherein the lipase mutant comprises:
an amino acid sequence with substitutions selected from the group consisting of P298T, P298T/H317P, P298T/H317P/V326S, P298T/T218S/S234F, P298T/H317P/P168L/A129S, and P298T/S234F/K161R/V326S, wherein the substitutions are relative to a parent amino acid sequence set forth in SEQ ID NO: 1;
wherein the lipase mutant maintains a triglyceride and lecithin hydrolysis activity and thermostability; and
wherein the method comprises:
expressing the lipase mutant from a culture of a recombinant yeast strain comprising an expression vector for the lipase mutant;
preparing a purified form of the lipase mutant from the culture; and
adding the purified form of the lipase mutant to a flour and water mix to obtain flour products.
US Pat. No. 10,167,457

NUCLEOBASE EDITORS AND USES THEREOF

President and Fellows of ...

1. A fusion protein comprising:(i) a Cas9 domain, wherein the Cas9 domain when in conjunction with a bound guide RNA (gRNA) specifically binds to a target nucleic acid sequence;
(ii) a cytidine deaminase domain, wherein the cytidine deaminase domain deaminates a cytosine base in a single-stranded portion of the target nucleic acid sequence when in conjunction with the Cas9 domain and the gRNA; and
(iii) an uracil glycosylase inhibitor (UGI) domain, wherein the UGI domain inhibits a uracil-DNA glycosylase.
US Pat. No. 10,167,201

HIGH MESO-SURFACE AREA, LOW SI/AL RATIO PENTASIL ZEOLITE

UOP LLC, Des Plaines, IL...


US Pat. No. 10,167,458

ALPHA-AMYLASE VARIANTS

1. An isolated variant of a parent alpha-amylase, comprising at least two substitutions at positions corresponding to positions 206 and 476 of the polypeptide of SEQ ID NO: 1, wherein the variant has at least 90%, but less than 100% sequence identity with the polypeptide of any of SEQ ID NOs 1, 2, 3, 4, 5, 6, 7, 10, 11 or 12, and wherein the variant has alpha-amylase activity.
US Pat. No. 10,166,178

DEPILATORY WAX COMPOSITION, METHOD FOR OBTAINING SAME AND USE THEREOF

GRUPO DRV PHYTOLAB, S.L.,...

1. A depilatory composition consisting of:60% to 70% by weight with respect to the total weight of the composition of synthetic resins selected from the group consisting of petroleum resin and colophony resin;
1% to 15% by weight with respect to the total weight of the composition of a carrier;
0.01% to 15% by weight with respect to the total weight of the composition of a hydrophilic cosmetic active agent,
wherein the carrier introduces the active agent into the depilatory composition, and wherein the carrier is obtained by reaction of liquid jojoba wax, mimosa wax and sunflower wax with polyglycerol-3 esters.
US Pat. No. 10,167,203

PREPARATION OF SUSPENSIONS

THE UNIVERSITY OF QUEENSL...

1. A method for preparing a suspension of LDH particles comprising the steps of:a) preparing LDH precipitates by coprecipitation to form a mixture of LDH precipitates and solution, wherein the LDH precipitates and the solution formed in step (a) are left in contact with each other for a period not exceeding 30 minutes;
b) separating the LDH precipitates from the solution;
c) washing the LDH precipitates to remove residual ions;
d) mixing the LDH precipitates with water; and
e) subjecting the mixture of LDH particles and water from step (d) to a hydrothermal treatment step by heating to a temperature of from greater than 80° C. to 150° C. for a period of about 1 hour to about 144 hours to form a dispersed suspension of non-aggregated LDH particles in water, wherein said LDH particles in suspension comprise platelets having a maximum particle dimension of up to 400 nm.
US Pat. No. 10,167,460

VARIANT ENZYMES

DANISCO US INC, , CA (US)...

1. A variant of a parent glycosyl hydrolase 61 (GH61) enzyme, wherein said variant has cellulase augmenting activity, and has at least 90% sequence identity to SEQ ID NO:3, wherein said variant comprises at least one amino acid substitution that is at position I4, wherein the position of each amino acid substitution corresponds to SEQ ID NO:3.
US Pat. No. 10,166,180

TREATMENT OF KERATINIZED TISSUES

1. A method for treating a keratinized tissue condition in a subject in need of treatment thereof, comprising:conducting one or more treatment cycles on the keratinized tissue in the subject in need of treatment thereof, each treatment cycle comprising:
contacting the keratinized tissue with an acid-activated gas-generating composition, the acid-activated gas-generating composition consisting of:
a gas generating agent; and
one or more of: water, aloe vera extract, panthenol, a sugar, a nonionic surfactant, a preservative, a water soluble alkali metal halide salt, a water soluble alkali earth metal salt, an ionic surfactant, a sugar, or sea trace elements;
contacting the keratinized tissue with an acid composition, the acid composition consisting of:
an acid; and
one or more of: water, aloe vera extract, panthenol, a sugar, a nonionic surfactant, a preservative, a water soluble alkali metal halide salt, a water soluble alkali earth metal salt, an ionic surfactant, a sugar, or sea trace elements; and
allowing the acid composition and the acid-activated gas-generating composition to react effective to generate a gas at the keratinized tissue,
the one or more treatment cycles being effective to at least partly ameliorate the keratinized tissue condition in the subject, the keratinized tissue condition selected from the group consisting of: acneiform eruptions, autoinflammatory syndromes, chronic blistering, conditions of the skin appendages, dermatitis, drug or agent eruptions, infection-related, papulosquamous hyperkeratosis, palmoplantar keratodermas, pruritis, psoriasis, conditions resulting from physical factors, or ionizing radiation-induced conditions.
US Pat. No. 10,167,461

POLYPEPTIDES HAVING CELLULOLYTIC ENHANCING ACTIVITY AND POLYNUCLEOTIDES ENCODING SAME

Novozymes, Inc., Davis, ...

4. A transgenic plant, plant part or plant cell transformed with the nucleic acid construct of claim 1 comprising a polynucleotide encoding the GH61 polypeptide having cellulolytic enhancing activity.
US Pat. No. 10,166,181

SLOW RELEASE PHARMACEUTICAL COMPOSITION MADE OF MICROGRANULES

1. A pharmaceutical composition of microgranules comprising 22.5 mg triptorelin in the form of triptorelin pamoate, wherein the pharmaceutical composition comprises: a) a first formulation of microgranules comprising approximately 20% (w/w) of triptorelin pamoate mixed with approximately 80% (w/w) PLGA, wherein the PLGA in the first formulation contains approximately 85% lactide and 15% glycolide; and b) a second formulation of microgranules comprising approximately 12% (w/w) triptorelin pamoate mixed with approximately 88% (w/w) poly(D,L lactide-co-glycolide) (PLGA), wherein the PLGA in the second formulation contains approximately 75% lactide and 25% glycolide, wherein the triptorelin is released from the pharmaceutical composition in an immediate amount within hours following injection and then constantly released over a period of at least 168 days.
US Pat. No. 10,167,463

MODIFIED CHYMOSIN POLYPEPTIDES

DSM IP ASSETS B.V., Heer...

1. A polypeptide having chymosin activity and comprising an amino acid sequence that has at least 90% sequence identity to SEQ ID NO:4, comprises at least one substitution modification relative to SEQ ID NO:4 selected from the group consisting of Q288H, and Q288R, and is capable of hydrolysing bovine alpha s1-casein at position F23F24 so as to form ?s1-I CN (f24-199) more rapidly than the polypeptide of SEQ ID NO:4.
US Pat. No. 10,170,796

LITHIUM SECONDARY BATTERY OF IMPROVED RATE CAPABILITY WITH CATHODE CONTAINING NICKEL MANGANESE COMPLEX OXIDE FOR HIGH-VOLTAGE APPLICATIONS

LG Chem, Ltd., (KR)

1. A lithium secondary battery comprising a cathode, an anode, a separator disposed between the cathode and the anode, and an electrolyte,wherein the electrolyte comprises a mixed solvent of a cyclic carbonate-based material and a propionate-based material, the cathode comprises a lithium manganese composite oxide represented by Formula 1 below as a cathode active material, and the anode comprises a lithium metal oxide represented by Formula 2 below as an anode active material:
LixMyMn2-yO4-zAz  (1)
wherein 0.9?x?1.2, 0 LiaM?bO4-cAc  (2)
wherein M? is at least one element selected from the group consisting of Ti, Sn, Cu, Pb, Sb, Zn, Fe, In, Al, and Zr; 0.1?a?4 and 0.2?b?4 wherein a and b are determined according to oxidation number of M?; 0?c<0.2 wherein c is determined according to oxidation number of A; and A is at least one monovalent or divalent anion,
wherein an amount of the cyclic carbonate-based material is in a range of 1 wt % to 30 wt % based on a total weight of the electrolyte,
wherein a mixing weight ratio of the cyclic carbonate-based material to the propionate-based material is in a range of 5 to 10:90 to 95,
wherein the lithium manganese composite oxide of Formula 1 is a lithium nickel manganese complex oxide (LNMO) represented by Formula 4 below:
LixNiyMn2-yO4  (4)
wherein 0.9?x?1.2 and 0.4?y?0.5, and
wherein the lithium metal oxide of Formula 2 is a lithium titanium oxide (LTO) represented by Formula 5 below:
LiaTibO4  (5)
 wherein 0.5?a?3 and 1?b?2.5.
US Pat. No. 10,167,466

SITE-SPECIFIC NUCLEASE SINGLE-CELL ASSAY TARGETING GENE REGULATORY ELEMENTS TO SILENCE GENE EXPRESSION

CSIR, Pretoria (ZA)

1. A method for silencing gene expression at a single cell level in vitro, the method comprising the steps of:(i) perturbing at least one chromosomal contact in the cell by by inducing a site specific double stranded break in a region of DNA involved in chromosomal contact; (ii) detecting the site of at least one double-stranded break; and (iii) detecting the effect of at least one perturbation on the transcriptional activity of at least one gene of interest, wherein the effect of the perturbation is abrogation of the transcriptional activity of the gene of interest and further wherein the site specific double stranded break in not induced in the gene of interest.
US Pat. No. 10,167,467

COMPOSITIONS COMPRISING EICOSAPENTAENOIC ACID AND MIPOMERSEN AND METHODS OF USE THEREOF

AMARIN PHARMACEUTICALS IR...

1. A composition comprising mipomersen and eicosapentaenoic acid, wherein the composition comprises at least about 80%, by weight of all fatty acids (and/or derivatives thereof) present, eicosapentaenoic acid, and no more than about 20%, by weight of all fatty acids (and/or derivatives thereof) present, docosahexaenoic acid or ester thereof.
US Pat. No. 10,167,468

METHODS FOR THE TREATMENT OF CARDIOVASCULAR FIBROSIS

UNIVERSITE DE LORRAINE, ...

1. A method for treating cardiovascular fibrosis induced by aldosterone in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an inhibitor of Neutrophil Gelatinase-Associated Lipocalin (NGAL) activity, wherein the inhibitor of NGAL activity is an anti-NGAL antibody.
US Pat. No. 10,167,469

CANCER TREATMENT AND IMMUNE SYSTEM REGULATION THROUGH FAT10 PATHWAY INHIBITION

President and Fellows of ...

1. A method of treating melanoma in a subject comprising administering to the subject an inhibitory nucleic acid specific for an mRNA that encodes FAT10.
US Pat. No. 10,166,189

LYOPHILIZED THERAPEUTIC PEPTIBODY FORMULATIONS

AMGEN INC., Thousand Oak...

1. A method for making a lyophilized therapeutic peptibody composition comprising the steps of:a) preparing a solution of a buffer, a bulking agent, a stabilizing agent, and optionally a surfactant;
wherein said buffer is comprised of 10 mM histidine and wherein the pH is about 5.0;
wherein said bulking agent is about 4% w/v mannitol;
wherein said stabilizing agent is about 2% w/v sucrose;
wherein said surfactant is about 0.004% w/v polysorbate-20; and
b) lyophilizing said therapeutic peptibody;
wherein said therapeutic peptibody comprises a structure of the formula
F1-(L1)e-P1-(L2)f-P2
Wherein the therapeutic peptibody is a dimer and wherein:
F1 is an Fc domain;
P1 and P2 each has the amino acid sequence of SEQ ID NO: 459;
L1 and L2 are each independently linkers;
e and f are each independently 0 or 1.
US Pat. No. 10,166,190

STABILIZED TACROLIMUS COMPOSITION

1. A sustained release tablet comprising (i) a dispersion of tacrolimus, (ii) 8-epitacrolimus, and (iii) a metal chelating agent that is an organic acid, wherein the tacrolimus is the sole active ingredient in the tablet and the tablet comprises a sufficient amount of the metal chelating agent such that the tablet comprises less than 0.5% by weight of the 8-epitacrolimus after 12 weeks of storage at 25° C. and 60% relative humidity, based upon 100% total weight of tacrolimus.
US Pat. No. 10,167,471

INHIBITION OF PCSK9 THROUGH RNAI

RXi Pharmaceuticals Corpo...

1. An RNAi construct for inhibiting expression of a PCSK9 gene, comprising a double-stranded RNA (dsRNA) of 25-27 base pairs in length, the dsRNA comprising: (1) a sense strand having a 5?-end and a 3?-end, wherein the sense strand comprises SEQ ID NO: 65, and wherein the sense strand comprises 12-14 and 10-12 consecutive 2?-modified ribose sugars at the 5?-end and the 3?-end nucleotides, respectively, and (2) an antisense strand having a 5?-end and a 3?-end, which hybridizes to the sense strand.
US Pat. No. 10,167,472

PME-1 AS A BIOMARKER TO PREDICT AND DIAGNOSE AN INCREASED RISK OF ENDOMETRIAL CANCER AND GENE SILENCING OF PME-1 TO INHIBIT EPITHELIAL TO MESENCHYMAL TRANSITION

Medical Diagnostic Labora...

1. A method of inhibiting epithelial to mesenchymal transition of an endometrial cell, comprising the steps of:(a) providing an endometrial cell
(b) providing a RNAi targeted against PME-1 gene, said RNAi hybridizes to a target sequence of PME-1 mRNA, wherein said RNAi is at least one RNAi selected from the group consisting of SEQ ID NOs: 2, 3, 5 and 7;
(c) exposing said endometrial cell to said RNAi, thereby decreasing PME-1 mRNA expression level,
wherein said RNAi inhibits said epithelial to mesenchymal transition as evidenced by at least one characteristic selected from the group consisting of reduced E-cadherin expression, reduced vimentin expression and reduced foci formation.
US Pat. No. 10,166,192

SOLUBILIZED COQ-10

1. An encapsulated composition comprising:coenzyme Q-10 or an analog thereof;
a sufficient quantity of d-limonene suitable to solubilize said coenzyme Q-10 and maintain it in solution at ambient temperature;
with the proviso that the composition does not include a carrier and the solubilized coenzyme Q-10 is not in an emulsion, suspension or elixir.
US Pat. No. 10,167,473

SIRNA AND THEIR USE IN METHODS AND COMPOSITIONS FOR INHIBITING THE EXPRESSION OF THE ORAI1 GENE

SYLENTIS SAU, Madrid (ES...

1. A method of treating an eye condition characterized by increased expression and/or activity of ORAI1 in a subject in need thereof, the method comprising:topically administering to the corneal surface of the eye of the subject an amount of an siRNA molecule that specifically targets the sequence of SEQ ID NO. 1 effective to decrease the expression and/or activity of ORAI1 in cells of the eye and to treat the eye condition, wherein said eye condition is an ocular allergy and/or conjunctivitis.
US Pat. No. 10,166,193

METHOD OF MAKING A SOFT GEL CAPSULE COMPRISING COQ-10 SOLUBILIZED IN A MONOTERPENE

1. A method of making a soft gel capsule comprising coenzyme Q-10, the method comprising:(a) mixing coenzyme Q-10 with a sufficient quantity of a monoterpene suitable to solubilize said coenzyme Q-10, an additional antioxidant, and an acceptable carrier to form a composition; and
(b) encapsulating said composition in a soft gel capsulewherein:the additional antioxidant is a tocopherol; and
the monoterpene is limonene.
US Pat. No. 10,166,194

HYDROCORTISONE CONTROLLED RELEASE FORMULATION

Diurnal Limited, Cardiff...

1. A method of treating a condition that would benefit from circadian delivery of hydrocortisone, comprising:orally administering at between approximately 20:00 hours to 24:00 hours a first pharmaceutical composition to a subject having the condition, wherein the first pharmaceutical composition comprises:
a drug core consisting of 20 mg hydrocortisone, a binding agent and a carrier of microcrystalline cellulose particles; and
a layer comprising a delayed release polymer that delays release of hydrocortisone from said core, wherein the layer comprising the delayed release polymer is in contact with said core, wherein said delayed release polymer is a mixture of (i) poly (methacrylic, methyl methyacrylic) in a ratio of 1:1 and (ii) poly (methacrylic, methyl methyacrylic) in a ratio of 1:2, wherein (i) and (ii) are at a ratio of 1:4; and
orally administering at between approximately 06:00 hours to 10:00 hours a second pharmaceutical composition, wherein the second composition comprises:
a drug core consisting of 10 mg hydrocortisone, a binding agent and a carrier of microcrystalline cellulose particles; and
a layer comprising a delayed release polymer that delays release of hydrocortisone from said core, wherein the layer comprising the delayed release polymer is in contact with said core, wherein said delayed release polymer is a mixture of (i) poly (methacrylic, methyl methacrylic) in a ratio of 1:1 and (ii) poly (methacrylic, methyl methacrylic) in a ratio of 1:2, wherein (i) and (ii) are at a ratio of 1:4;
wherein relative bioavailability of the total 30 mg hydrocortisone in the first and second pharmaceutical compositions is increased relative to when compared to relative bioavailability of a delayed-sustained formulation of hydrocortisone, and
wherein administering the first and second pharmaceutical compositions reproduces the normal circadian release of cortisol,
thereby treating a condition that would benefit from circadian delivery of hydrocortisone.
US Pat. No. 10,167,475

APTAMERS FOR PURIFYING AND QUANTIFYING GELSOLIN AND ITS VARIANTS

1. DNA aptamers represented by SEQ ID No. 6 capable of binding a protein gelsolin represented by SEQ ID No. 1 or its variants represented by SEQ ID No. 2 and 3.
US Pat. No. 10,170,808

BATTERY PACK

SAMSUNG SDI CO., LTD., Y...

1. A battery pack, comprising:a plate-shaped cooling plate, the plate-shaped cooling plate including a stopper on a bottom surface thereof at one lengthwise side of the plate-shaped cooling plate;
a plurality of battery modules, the plurality of battery modules being mounted on a planar top surface of the plate-shaped cooling plate such that surfaces of the battery modules are aligned in a coplanar manner and together directly contact the planar top surface of the plate-shaped cooling plate; and
at least one bracket on the one lengthwise side of the plate-shaped cooling plate, wherein one side of the at least one bracket is coupled with the stopper and the bottom surface of the plate-shaped cooling plate by welding,
wherein each battery module of the plurality of battery modules includes a fixing part thereon, and
wherein another side of the at least one bracket is coupled with the fixing part with a fixing member.
US Pat. No. 10,166,196

VEGETARIAN MICROCAPSULES

DSM NUTRITIONAL PRODUCTS ...

1. A microcapsule, comprising: an agglomeration of primary microcapsules and a loading substance, each individual primary microcapsule having a primary shell, wherein the loading substance is encapsulated by the primary shell, wherein the agglomeration is encapsulated by an outer shell, and wherein the primary shell and the outer shell both comprise a complex coacervate of a first protein and a second polymer,wherein the first protein is pea protein or soy protein;and the second polymer is selected from the group consisting of agar, gellan gum, gum arabic, casein, cereal prolamine, pectin, alginate, carrageenan, xanthan gum, canola protein, dilutan gum, locus bean gum, and welan gum; andwherein the primary and outer shells are thermally crosslinked.
US Pat. No. 10,166,197

SUGAR ESTER NANOPARTICLE STABILIZERS

1. A method for preparing a solid dosage form containing nanoparticles, the method comprising the steps of:(a) reducing particle size of at least one pharmaceutically active ingredient dispersed in a solution containing a sugar ester nanoparticle stabilizer to form a nanosuspension; and
(b) drying the nanosuspension of step (a) to form the solid dosage form,
wherein the sugar ester nanoparticle stabilizer is a sugar fatty acid ester, and
wherein no excipient other than the sugar ester nanoparticle stabilizer is added for stabilizing the nanoparticles, and wherein the ratio of the total amount of the sugar ester nanoparticle stabilizer to the total amount of the pharmaceutically active ingredient in the solid dosage form is equal to or less than 1:1.
US Pat. No. 10,166,198

SOLID NANOPARTICLE WITH INORGANIC COATING

Nanexa AB, Uppsala (SE)

1. A method of preparing a controlled or delayed release pharmaceutical composition in a form of a sterile injectable or infusible suspension of particles comprising:i. a plurality of coated particles of a size that is from 0.1 ?m to 50 ?m, said coated particles having a solid core comprising a drug, said solid core being enclosed by one or more metal oxide materials; and
ii. a pharmaceutically and parentally acceptable diluent,the method comprising the sequential steps of:(1) applying an initial coating of at least one metal oxide to said solid cores in an atomic layer deposition reactor;
(2) discharging the coated particles from the reactor and subjecting the coated particles to agitation to disaggregate particle aggregates formed during step (1);
(3) reintroducing the disaggregated, coated particles from step (2) into an atomic layer deposition reactor and applying a further coating of at least one metal oxide to the reintroduced particles;
(4) optionally repeating steps (2) and (3) one or more times to increase a total thickness of the one or more metal oxide materials that enclose said solid core; and
(5) admixing said coated particles obtained from step (3) or step (4) with said pharmaceutically and parenterally acceptable diluent to form said pharmaceutical composition.
US Pat. No. 10,167,222

SELENIUM-FREE SUNGLASS MATERIAL WITH BROWN TINT

Corning Incorporated, Co...

1. A glass comprising B2O3, SiO2, and Fe, said Fe including ferric ion (Fe3+) and ferrous ion (Fe2+), said glass lacking Se and having (i) a tint with a chromaticity coordinate x in the range from 0.37-0.65, and (ii) a concentration of said ferrous ion (Fe2+) sufficient to provide an average percent transmittance (% T) over the wavelength range from 780 nm-2000 nm, for a thickness of 1.9 mm, of less than 3%.
US Pat. No. 10,166,200

BUFFERED OXYGEN THERAPEUTICS

NuvOx Pharma LLC, Tucson...

1. An oxygen therapeutic composition, comprising:water;
a perfluorocarbon material selected from perfluoropentane and perfluorohexane;
a buffer; and
dipalmitoylphosphatidylcholine and/or dipalmitoylphosphatidylcholine mixed with dipalmitoylphosphatidylethanolamine with covalently linked poly(ethylene glycol) (PEG) with molecular mass 5000;wherein:the buffer comprises NaH2PO4 and Na2HPO4 and stabilizes a pH of the composition at between about 6.5 to about 7.5; and
the composition comprises a viscosity of about 2.0 to about 3.5 mPas.
US Pat. No. 10,167,482

GENES AND USES FOR PLANT ENHANCEMENT

Monsanto Technology LLC, ...

1. A plant cell nucleus comprising a stably integrated recombinant DNA construct wherein said recombinant DNA comprises a heterologous promoter that is functional in said plant cell and that is operably linked to a protein coding DNA encoding at least one protein having an amino acid sequence comprising at least 95% amino acid sequence identity to SEQ ID NO:936 and having the function of SEQ ID NO:936and wherein said recombinant DNA construct is stably integrated into a chromosome in a plant cell nucleus which is selected by screening a population of transgenic plants that have said recombinant DNA and an enhanced trait as compared to control plants that do not have said recombinant DNA in their nuclei; and wherein said enhanced trait is selected from group of enhanced traits consisting of increased yield and enhanced nitrogen use efficiency.
US Pat. No. 10,167,483

HERBICIDE RESISTANCE GENES

Dow AgroSciences LLC, In...

1. An expression cassette for expression in a plant cell, comprising a polynucleotide operably linked to a heterologous plant promoter or a plant virus promoter, wherein said polynucleotide encodes a protein that catalyzes degradation of phenoxy auxin and pyridyloxy auxin herbicides, wherein the polynucleotide that encodes said protein comprises SEQ ID NO:3.
US Pat. No. 10,167,227

FIBERGLASS MATERIALS, METHODS OF MAKING, AND APPLICATIONS THEREOF

1. A composite glass material comprising:Na2O about 2.1 to about 8.2 weight percent;
SiO2 55 to 70 weight percent;
Al2O3 5 to 11 weight percent;
CaO 15 to 20 weight percent;
MgO 1 to 3 weight percent; and
K2O less than about 0.2 weight percent.
US Pat. No. 10,167,484

COMPOSITIONS AND METHODS FOR CONTROL OF INSECT INFESTATIONS IN PLANTS

Monsanto Technology LLC, ...

1. A method for controlling Western Corn Rootworm infestation on a plant, comprising topically applying to the plant a pesticide composition comprising a dsRNA targeting for suppression an essential gene in the Western Corn Rootworm and providing the plant in the diet of the Western Corn Rootworm, wherein the plant comprises a nucleic acid sequence encoding at least a first Bacillus thuringiensis insecticidal protein for controlling the Western Corn Rootworm.
US Pat. No. 10,167,228

LITHIUM INFUSED RAW FLY ASH FOR THE PRODUCTION OF HIGH STRENGTH CEMENTITIOUS PRODUCTS

VHSC, LTD., Tortola (VG)...

1. A method for producing a cementitious product having a greater than Grade 100 slag performance, the method comprising:mixing raw fly ash with a lithium compound to produce the cementitious product, wherein 17.5% or greater of the raw fly ash includes calcium-containing minerals.
US Pat. No. 10,167,485

PRODUCTION OF VIRAL VECTORS

The Regents of the Univer...

1. A method for producing helper-dependent adenoviral vectors comprising:a) providing:
a helper-dependent adenoviral DNA comprising a first origin of replication, a helper viral DNA comprising a second origin of replication, wherein said first origin of replication and said second origin of replication are not linked to terminal protein or any terminal protein remnant,
a vector comprising a nucleic acid encoding an adenoviral protein IX operably linked to a heterologous promoter, and
target cells; and
b) transfecting said target cells with said helper-dependent adenoviral DNA, said helper viral DNA, and said vector comprising a nucleic acid encoding an adenoviral protein IX operably linked to a heterologous promoter under conditions such that helper-dependent adenoviral vectors are produced.
US Pat. No. 10,167,486

VECTORS AND METHODS FOR LONG-TERM IMMUNE EVASION TO PROLONG TRANSPLANT VIABILITY

NATIONAL INSTITUTE OF TRA...

1. A kit for altering allogeneic human cells for a human recipient, the kit comprising:a set of lentivirus vectors wherein each of the lentivirus vectors expresses a sequence targeting a consensus conserved nucleic acid sequence, which when expressed in cells, functions as a negative modulator for nucleic acid encoding a domain having a mismatch in an HLA protein and wherein the set of lentivirus vectors comprises individual lentivirus vectors that correspond to individual HLA mismatches for a set of HLA mismatches that consist of HLA Class I mismatches and at least one HLA Class II mismatch;
wherein the kit is for treatment of human cells by an appropriate subset of the set of lentivirus vectors based at least in part on a determined subset of the set of HLA mismatches between a human donor and a human recipient or between human cells and a human recipient.
US Pat. No. 10,166,206

TOPICAL COMPOSITIONS AND METHODS FOR MAKING AND USING SAME

SEBELA INTERNATIONAL BERM...

1. A gel composition for topical administration comprising:(i) naftifine or a pharmaceutically acceptable salt thereof, present in an amount of from about 0.5 wt % to about 4 wt %;
(ii) a solvent comprising a glycol solvent component and an alkyl alcohol solvent component, present in an amount of from about 10 wt % to about 50 wt %;
(iii) a hydroxy cellulose, present in an amount of from about 0.75 wt % to about 2.25 wt %;
(iv) a polysorbate solubilizing agent present in an amount of from about 3 wt % to about 8 wt %;
(v) an amine pH adjuster in an amount of from about 0.12 wt % to about 0.23 wt %; and
one or more of: water, a preservative, a chelating agent, a coloring agent, and a fragrance, wherein the gel composition exhibits an in vitro release rate under the SUPAC-SS guidance of from about 2700 ?g/cm2/hr1/2 to about 3134 ?g/cm2/hr1/2.
US Pat. No. 10,167,230

ULTRA STABLE TILE BACKER BOARD FORMULATION

1. A tile backer board comprising the product of:a. forming a cementitious material that is the product of:
(i) blending
a) 29 wt. % to 40 wt. %, based on the final total weight of the cementitious material, of a magnesium oxide dry powder containing 80 wt. % to 98 wt. % of magnesium oxide, the magnesium oxide powder having a surface area of from 5 m2/g to 50 m2/g and an average particle size of from about 0.3 ?m to about 90 ?m, and wherein more than about 90 wt. % of the particles of the magnesium oxide powder have a particle size of less than or equal to about 40 ?m, with
b) 14 wt. % to 18 wt. %, based on the final total weight of the cementitious material, of an aqueous solution of magnesium chloride, the aqueous solution of magnesium chloride comprising 20 wt. % to 30 wt. % of magnesium chloride,
and reacting the magnesium oxide and the magnesium chloride to form a liquid suspension;
(ii) mixing the liquid suspension for from 2 minutes to 10 minutes;
(iii) adding 0.1 wt. % to 10 wt. %, based on the final total weight of the cementitious material, of a stabilizing material to the mixed liquid suspension, wherein the stabilizing material is:
1) an aqueous solution comprising 55 wt. % to 65 wt. % of phosphorous acid (H3PO3); or
2) an aqueous solution comprising 80 wt. % to 90 wt. % of phosphoric acid (H3PO4); and
(iv) allowing the liquid suspension with the stabilizing material to react for from 1 minute to 4 minutes to form an amorphous phase cementitious material;
b. blending 35 wt. % to 79.9 wt. %, based on the final total weight of the tile backer board, of the formed amorphous phase cementitious material with 0.1 wt. % to 30 wt. %, based on the final total weight of the tile backer board, of an aggregate comprising particles having a diameter from 1 nm to 10 nm, wherein the aggregate comprises at least one selected from the group consisting of wood, perlite, styrene-based foam beads, calcium carbonate powder, and glass particulates, thereby forming a concrete; and
c. pouring the formed concrete over 0.1 wt. % to 2 wt. %, based on the final total weight of the tile backer board, of a reinforcing material that cures into the tile backer board, the reinforcing material comprising a non-woven or woven silica-containing mat or a non-woven or woven hydrocarbon-containing mat;
wherein a portion of the amorphous phase cementitious material grows a plurality of crystals, each crystal having a molecular weight of from 280 to 709 and being encapsulated by the amorphous phase cementitious material;
wherein a majority of the stabilizing material is consumed during curing into a nano-molecular veneer over the crystals while increasing the surface area of the plurality of crystals by 2% to 49%; and
wherein the nano-molecular veneer is insoluble in water and protects the plurality of crystals from degradation in water at temperatures of from 20° C. to 60° C. for from 24 hours to 56 days.
US Pat. No. 10,167,231

PROCESS FOR MAKING ULTRA STABLE TILE BACKER BOARD

1. A process of making a tile backer board comprising:a. forming a cementitious material, comprising:
(i) blending
a) 29 wt. % to 40 wt. %, based on the final total weight of the cementitious material, of a magnesium oxide dry powder containing 80 wt. % to 98 wt. % of magnesium oxide, the magnesium oxide powder having a surface area of from 5 m2/g to 50 m2/g and an average particle size of from about 0.3 ?m to about 90 ?m, and wherein more than about 90 wt. % of the particles of the magnesium oxide powder have a particle size of less than or equal to about 40 ?m, with
b) 14 wt. % to 18 wt. %, based on the final total weight of the cementitious material, of an aqueous solution of magnesium chloride, the aqueous solution of magnesium chloride comprising 20 wt. % to 30 wt. % of magnesium chloride,
and reacting the magnesium oxide and the magnesium chloride to form a liquid suspension;
(ii) mixing the liquid suspension for from 2 minutes to 10 minutes;
(iii) adding 0.1 wt. % to 10 wt. %, based on the final total weight of the cementitious material, of a stabilizing material to the mixed liquid suspension, wherein the stabilizing material is:
1) an aqueous solution comprising 55 wt. % to 65 wt. % of phosphorous acid (H3PO3); or
2) an aqueous solution comprising 80 wt. % to 90 wt. % of phosphoric acid (H3PO4);
(iv) allowing the liquid suspension with the stabilizing material to react for from 1 minute to 4 minutes to form an amorphous phase cementitious material;
b. blending 35 wt. % to 79.9 wt. %, based on the final total weight of the tile backer board, of the formed amorphous phase cementitious material with 0.1 wt. % to 30 wt. %, based on the final total weight of the tile backer board, of an aggregate comprising particles having a diameter from 1 nm to 10 nm, wherein the aggregate comprises at least one selected from the group consisting of wood, perlite, styrene-based foam beads, calcium carbonate powder, and glass particulates, thereby forming a concrete; and
c. pouring the formed concrete over 0.1 wt. % to 2 wt. %, based on the final total weight of the tile backer board, of a reinforcing material that cures into the tile backer board, the reinforcing material comprising a non-woven or woven silica-containing mat or a non-woven or woven hydrocarbon-containing mat;
wherein a portion of the amorphous phase cementitious material grows a plurality of crystals, each crystal having a molecular weight of from 280 to 709 and being encapsulated by the amorphous phase cementitious material;
wherein a majority of the stabilizing material is consumed during curing into a nano-molecular veneer over the crystals while increasing the surface area of the plurality of crystals by 2% to 49%; and
wherein the nano-molecular veneer is insoluble in water and protects the plurality of crystals from degradation in water at temperatures of from 20° C. to 60° C. for from 24 hours to 56 days.
US Pat. No. 10,167,488

HETEROLOGOUS PATHWAY TO PRODUCE TERPENES

The Regents of the Univer...

1. A cell genetically engineered to express a heterologous metabolic pathway comprising heterologous Bombyx mori and/or Choristoneura fumiferana mevalonate pathway enzymes, wherein the cell produces a product of the metabolic pathway that is a C16 terpene, wherein the mevalonate pathway enzymes comprise ?-hydroxy ?-methylglutaryl-CoA synthase (HMGS), ?-hydroxy ?-methylglutaryl-CoA reductase (HMGR), mevalonate kinase (MevK), mevalonate phosphate kinase (MevPK), mevalonate pyrophosphate decarboxylase (MevPPD), isopentenyl pyrophosphate isomerase (IPPI) and farnesyl pyrophosphate synthase (FPPS), wherein the metabolic pathway further comprises a terpene cyclase.
US Pat. No. 10,166,208

ORAL CARE COMPOSITION

Next Science IP Holdings ...

1. An oral care composition useful for treating a microbe-induced condition of the oral cavity of a subject in need thereof, said oral care composition consisting of (1) an oral rinse containing eucalyptol, thymol, menthol, and methyl salicylate in an alcohol vehicle, (2) an aqueous composition consisting of dissociation products of at least one base and a phosphate or sulfate in water, and (3) from 0.5 to 1.8 g/L of at least one cationic surfactant, said oral care composition having a pH of from 7.5 to 10 and an osmolarity of from 1.25 to 2.5 Osm/L.
US Pat. No. 10,167,232

PROCESS FOR MAKING AN ULTRA STABLE CEMENTITIOUS CONSTRUCTION MATERIAL

1. A process of making a cementitious material comprising:(i) blending
a) 29 wt. % to 40 wt. %, based on the final total weight of the cementitious material, of a magnesium oxide dry powder containing 80 wt. % to 98 wt. % of magnesium oxide, the magnesium oxide powder having a surface area of from 5 m2/g to 50 m2/g and an average particle size of from about 0.3 ?m to about 90 ?m, and wherein more than about 90 wt. % of the particles of the magnesium oxide powder have a particle size of less than or equal to about 40 ?m, with
b) 14 wt. % to 18 wt. %, based on the final total weight of the cementitious material, of an aqueous solution of magnesium chloride, the aqueous solution of magnesium chloride comprising 20 wt. % to 30 wt. % of magnesium chloride,
 and reacting the magnesium oxide and the magnesium chloride to form a liquid suspension;
(ii) mixing the liquid suspension for from 2 minutes to 10 minutes;
(iii) adding 0.1 wt. % to 10 wt. %, based on the final total weight of the cementitious material, of a stabilizing material to the mixed liquid suspension, wherein the stabilizing material is:
1) an aqueous solution comprising 55 wt. % to 65 wt. % of phosphorous acid (H3PO3); or
2) an aqueous solution comprising 80 wt. % to 90 wt. % of phosphoric acid (H3PO4);
(iv) allowing the liquid suspension with the stabilizing material to react for from 1 minute to 4 minutes to form an amorphous phase cementitious material;wherein a portion of the amorphous phase cementitious material grows a plurality of crystals, each crystal having a molecular weight of from 280 to 709 and being encapsulated by the amorphous phase cementitious material;wherein a majority of the stabilizing material is consumed during curing into a nano-molecular veneer over the crystals while increasing the surface area of the plurality of crystals by 2% to 49%; andwherein the nano-molecular veneer is insoluble in water and protects the plurality of crystals from degradation in water at temperatures of from 20° C. to 60° C. for from 24 hours to 56 days.
US Pat. No. 10,167,489

MICROBIAL OILS WITH LOWERED POUR POINTS, DIELECTRIC FLUIDS PRODUCED THEREFROM, AND RELATED METHODS

Corbion Biotech, Inc., S...

1. A method of producing a microalgal oil, the method comprising:a. cultivating a genetically engineered Chlorella or Prototheca cell engineered to ablate or downregulate expression of an endogenous fatty acyl-ACP thioesterase gene until the microbe has at least 10% oil by dry weight;
b. separating the oil from the microbe; and optionally
c. subjecting the oil to refining, bleaching, deodorizing or degumming to produce RBD microbial oil.
US Pat. No. 10,169,541

METHOD AND SYSTEMS FOR CHARACTERIZING SKIN RELATED CONDITIONS

uBiome, Inc., San Franci...

1. A system for evaluating a skin-related condition in relation to a user, the system comprising:a handling network operable to collect containers comprising material from a set of users, the handling network comprising:
a library preparation system operable to fragment and perform multiplex amplification on the material using a primer compatible with a genetic target associated with the skin-related condition;
a sequencing system operable to determine microorganism sequences from sequencing the material;
a microbiome characterization system operable to:
determine microbiome composition data and microbiome functional diversity data based on an alignment between the microorganism sequences and reference sequences associated with the skin-related condition,
collect supplementary data associated with the skin-related condition for the set of users, and
transform the supplementary data and features extracted from the microbiome composition data and the microbiome functional diversity data into a characterization model for the skin-related condition; and
a treatment system operable to provide a treatment to the user for the skin-related condition based on characterizing the user with the characterization model in relation to the skin-related condition.
US Pat. No. 10,166,209

METHODS OF REDUCING APOLIPOPROTEIN C-III

Amarin Pharmaceuticals Ir...

1. A method of reducing an apolipoprotein C-III (“APOC3”) level of a subject on statin therapy and having baseline fasting triglycerides of about 200 mg/dl to about 499 mg/dl, the method comprising administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of at least about 95%, by weight of all fatty acids present, ethyl eicosapentaenoate per day, wherein the APOC3 level is reduced by at least about 15%.
US Pat. No. 10,167,233

PRODUCT HAVING A HIGH ALUMINA CONTENT

1. A sintered refractory product having the shape of a block and consisting of:grains having a size of greater than 100 ?m, referred to as “coarse grains”, the coarse grains forming an aggregate, and
a matrix bonding said coarse grains and consisting of grains having a size of less than or equal to 100 ?m,the aggregate representing between 45% and 90% by weight of the product,said product having a composition such that, as a weight percentage on the basis of the oxides:Al2O3>80%,
SiO2<15%,
Na2O<0.15%
Fe2O3<0.05%,
CaO<0.1%,
the other oxides constituting the balance to 100%,the content of Na2O in the matrix being greater than 0.010%, as a weight percentage on the basis of the weight of the product, the product having crystalline phases.
US Pat. No. 10,167,490

ERGOTHIONEINE PRODUCTION THROUGH METABOLIC ENGINEERING

Ergo Health LLC, Newton,...

1. A process for preparing ergothioneine, the process comprising:(i) incubating histidine or hercynine with a reaction mixture comprising recombinantly expressed:
(a) EgtA protein,
(b) EgtB protein,
(c) EgtC protein,
(d) EgtD protein, and
(e) EgtE protein, wherein the EgtE protein is produced from recombinant coexpression with a gene encoding a FAD synthetase to facilitate EgtE production; and
(ii) isolating ergothioneine from the reaction mixture.
US Pat. No. 10,169,542

SYSTEMS AND METHODS FOR AUTOMATICALLY DETERMINING MYOCARDIAL BRIDGING AND PATIENT IMPACT

HeartFlow, Inc., Redwood...

1. A computer-implemented method for determining risks of myocardial bridging in a patient, the method comprising:receiving a plurality of patient-specific multiphase images;
generating, based on the plurality of multiphase images, a patient-specific mesh model of the patient's heart;
computing cross-sectional areas for one or more segments of the patient-specific mesh model;
computing, from the computed cross-sectional areas of the patient-specific mesh model, systolic compression of at least one selected segment of the segments of the patient-specific mesh model;
computing, at the at least one selected segment, a value of a hemodynamic characteristic using a computational fluid dynamics or structural mechanics analysis; and
outputting a coronary risk assessment for the patient or outputting a hemodynamic significance of the systolic compression in the patient-specific mesh model, based on the computed value of the hemodynamic characteristic.
US Pat. No. 10,166,210

METHODS OF SUBTYPING CRC AND THEIR ASSOCIATION WITH TREATMENT OF COLON CANCER PATIENTS WITH OXALIPLATIN

NSABP Foundation, Inc., ...

1. A method of treating stage III colon cancer patients comprising:a) obtaining a colon cancer tumor tissue sample from a patient with stage III colon cancer,
b) contacting a genetic sample from said colon cancer tumor tissue sample with a plurality of specific genetic sequence binding targets and measuring the expression level of a panel of 72 genes, wherein the 72 genes are AKAP12, ANKRD44, BGN, BHLHE41, BMP7 C8orf84, CAB39L, CDKN2B, CKMT2, COL11A1, COMP, CPE, CSGALNACT1, CXCL10, CXCL11, CXCL13, CXCL2, CXCL9, CYP1B1, DAPK1, DCBLD2, DPEP1, EPB41L4B, ERAP2, F5, FAP, FGL2, FN1, FNDC1, GBP1, GBP4, GPX3, GRM8, GZMB, HGD, HOXA13, HSD17B2, ID4, IDO1, IL8, INHBA, MFAP5, MGP, MMP11, MMP28, NFIB, OAS2, PAPPA, PIGR, PLA2G12B, POU2AF1, PRAP1, PROM2, PSMB9, PTPRC, ROBO1, SDC2, SELL, SERPINE1, SFRP2, SGK2, SLC4A4, SPARC, SPP1, SSPN, STC1, TACSTD2, TGFBR3, TM4SF1, TYMS, VCAN, and VNN1,
c) obtaining a gene expression signature for said colon cancer tumor tissue from the gene expression level of the panel of 72 genes in b),
d) identifying said colon cancer tumor tissue as being a subtype responsive to oxaliplatin, and
e) administering oxaliplatin in combination with 5?fluorouracil and leucovorin (FULV) to said patient with Stage III colon cancer in a).
US Pat. No. 10,167,491

METHODS FOR DEGRADING OR CONVERTING CELLULOSIC MATERIAL

1. An enzyme composition for degrading or converting a cellulosic material to fermentable sugars comprising one or more enzymes having cellulolytic and/or hemicellulolytic activity and a polypeptide having catalase activity, wherein the presence of the polypeptide having catalase activity increases the production of fermentable sugars, as compared to a degradation or conversion of a cellulosic material not in the presence of a polypeptide having catalase activity, wherein the polypeptide having catalase activity is selected from the group consisting of:(a) a polypeptide having at least 70% sequence identity to the amino acid sequence of SEQ ID NO: 2, the sequence of amino acids 20 to 733 of SEQ ID NO: 4, or the sequence of amino acids 20 to 765 of SEQ ID NO: 6;
(b) a polypeptide encoded by a polynucleotide that hybridizes under high stringency conditions with (i) the sequence of SEQ ID NO: 1, the nucleic acid sequence of nucleotides 58 to 2418 of SEQ ID NO: 3, or the nucleic acid sequence of nucleotides 58 to 3040 of SEQ ID NO: 5, (ii) the cDNA sequence thereof, or (iii) the full-length complement of (i) or (ii);
(c) a polypeptide encoded by a polynucleotide having at least 70% sequence identity to the sequence of SEQ ID NO: 1, the nucleic acid sequence of nucleotides 58 to 2418 of SEQ ID NO: 3, the nucleic acid sequence of nucleotides 58 to 3040 of SEQ ID NO: 5, or the cDNA sequence thereof; and
(d) a fragment of the polypeptide of (a), (b), or (c) that has catalase activity.
US Pat. No. 10,167,492

PROCESS FOR MANIPULATING THE LEVEL OF GLYCAN CONTENT OF A GLYCOPROTEIN

AMGEN INC., Thousand Oak...

1. A method for manipulating the fucosylated glycan content on a recombinant protein comprising inoculating a bioreactor with mammalian host cells expressing the recombinant protein, culturing the mammalian host cells in a serum free, chemically defined cell culture medium; wherein the cell culture medium includes from 10 to 100 ppb copper and from 50 to 1000 nM manganese, at pH 7.0, harvesting the recombinant protein produced by the host cell, wherein the level of afucosylated glycans on the recombinant protein increases compared to the afucosylated glycan level obtained in the same cell culture medium at a lower pH.
US Pat. No. 10,166,219

FORMULATIONS AND METHODS OF MANUFACTURING FORMULATIONS FOR USE IN COLONIC EVACUATION

Redhill Bipharma Ltd., T...

1. A coated tablet, comprising: an intra-granular fraction combined with an extra-granular fraction, and a coating layer,wherein the intra-granular fraction includes granules comprising micronized sodium picosulfate, microcrystalline cellulose, magnesium oxide, and crospovidone, and wherein the intra-granular fractions excludes sodium starch glycolate,
wherein the extra-granular fraction includes one or more organic acids, microcrystalline cellulose, and crospovidone, and wherein the extra-granular fraction excludes sodium starch glycolate and magnesium stearate,
wherein the organic acid is one of ascorbic acid, citric acid, tartaric acid, or combinations thereof, and
wherein the coating layer delays dissolution beyond the mouth of a patient.
US Pat. No. 10,167,501

METHODS AND APPARATUS FOR QUANTIFICATION OF NUCLEIC ACID AMPLIFICATION BY MONITORING IMPEDANCES

AUCKLAND UNISERVICES LIMI...

1. A method for amplifying a target nucleic acid, the method comprising the steps ofa) providing a reaction volume comprising
(i) a first electrode comprising an electrochemically-active conducting polymer,
(ii) a first single-stranded nucleic acid molecule capable of hydridizing to a first portion of a target nucleic acid sequence, wherein the first nucleic acid molecule is covalently attached to the electrochemically-active conducting polymer, and
(iii) a second electrode;
b) providing a reaction mixture to the reaction volume, the reaction mixture comprising
(i) the target nucleic acid,
(ii) a second single-stranded nucleic acid molecule comprising nucleic acid sequence complementary to a second portion of the target nucleic acid sequence,
(iii) a nucleic acid polymerase,
(iv) ferro-ferricyanide, and
(v) a supply of reagents for a nucleic acid amplification reaction;
c) performing a polymerase chain reaction, and
d) measuring the impedance of the first electrode at least once during the polymerase chain reaction.
US Pat. No. 10,167,503

MUTANT PORES

Oxford Nanopore Technolog...

1. A mutant Mycobacterium smegmatis porin (Msp) monomer comprising a variant of the sequence that is at least 90% identical to the sequence of SEQ ID NO: 2, which comprises a cap forming region and a barrel forming region, wherein the variant:(a) does not comprise aspartic add (D) at position 90;
(b) does not comprise aspartic acid (D) at position 91;
(c) comprises aspartic add (D) or glutamic add (E) at position 93; and
(d) comprises one or more amino acid modifications in the cap forming region and/or the barrel forming region of SEQ ID NO: 2 such that, when the mutant Msp monomer forms a pore, the net negative charge of inward facing amino acids is decreased, and wherein the cap forming region comprises amino acids 1 to 72 and 122 to 184 of SEQ ID NO: 2.
US Pat. No. 10,168,271

MICROPARTICLES HAVING REFERENCE MARKERS ARRANGED IN DIFFERENT CONCENTRATIONS

The General Hospital Corp...

1. A method of sorting a plurality of cells, the method comprising:arranging a plurality of microparticles into an array on a substrate in a microfluidic device, wherein each microparticle of the plurality of microparticles comprises a plurality of reference markers embedded within the microparticle or attached to a surface of the microparticle
wherein the plurality of reference markers are arranged in two or more regions, each region having a different overall concentration of the reference markers,
wherein the plurality of reference markers comprise chemokines, and wherein the plurality of reference markers arranged in the two or more regions establish a chemokine concentration gradient within the microparticle or along the surface of the microparticle, and
wherein the microparticle is tubular and has an opening that extends through the microparticle;
introducing a plurality of cells to the array of microparticles under conditions that enable at least some of the cells to adhere to the microparticles;
removing the plurality of microparticles, to which the cells are adhered, from the substrate;
transferring the plurality of microparticles, to which the cells are adhered, to a detection region; and
detecting, for each of two or more microparticles that pass through the detection region, a microparticle feature; and
sorting the two or more microparticles based on the detected features, wherein the detected features are related to a phenotype of the cells.
US Pat. No. 10,167,504

METHOD OF SEQUENCING

GENESEQUE AS, Trondheim ...

1. A method for determining a nucleotide sequence of a polynucleotide, preferably immobilised on a solid support, comprising the steps of:(i) contacting said polynucleotide with a) at least a first and second test probe each comprising a portion which may be complementary to one or more bases in said polynucleotide, and optionally, in addition, b) at least one test complementary base each of which may be complementary to a base in said polynucleotide, and covalently binding said first or second test probe to said polynucleotide when said portion of said first or second test probe is complementary to said one or more bases in said polynucleotide by ligation of said first or second test probe to said polynucleotide;
(ii) adding a first enzyme capable of removing at least part of said first test probe and at least one base of the polynucleotide being sequenced by a cleavage reaction if said first test probe bound to said polynucleotide and then sequentially adding at least a second enzyme capable of removing at least part of said second test probe if said second test probe bound to said polynucleotide, wherein each of said enzymes is different and specific for said first or second test probe;
(iii) optionally repeating steps (i) and (ii) with at least two different test probes and at least two enzymes wherein said enzymes may be the same or different to the enzymes used in step (ii) until a test probe which has a portion which is complementary to said one or more bases has bound to said polynucleotide and optionally, in addition, a test complementary base has bound to said polynucleotide, wherein only one test probe used in step (i) or step (iii) has a portion which is complementary to said one or more bases in said polynucleotide and optionally, in addition, only one test complementary base used in step (i)or step (iii) is complementary to a base in said polynucleotide, and said only one test probe binds to said polynucleotide in step (i) or step (iii) and optionally, in addition, said only one test complementary base binds to said polynucleotide in step (i) or (iii);
(iv) determining which test complementary base and/or complementary portion of the test probe bound to said one or more bases of the polynucleotide by determining whether said test complementary base and/or test probe bound to said polynucleotide during steps (i), (ii) or (iii) to thereby identify said one or more bases of the polynucleotide;
wherein each cycle of steps (i) to (iv) is performed one or more times, and in each cycle one or more bases of said sequence are identified, and wherein determining step (iv) comprises determining the presence, absence or level of a signal associated with said test probe and/or test complementary base, wherein the presence of signal is indicative of binding of said test complementary base and/or test probe and said signal is provided by a label associated with said test probe and/or test complementary base, and wherein said label is a bead and wherein the same bead is used for each test probe and/or test complementary base and said label is used to identify the one or more bases which are identified by determining which test probe is cleaved during step (ii).
US Pat. No. 10,166,736

SAG-RESISTANT SUBSTRATES AND METHODS OF PREPARING AND USING SAME

AWI Licensing LLC, Wilmi...

1. A substrate comprising:a core comprising a plurality of open cells;
a first facing layer attached to a first major side of the core by a first adhesive; and
a second facing layer attached to a second major side of the core by a second adhesive;wherein the glass transition temperature of the second adhesive is greater than the glass transition temperature of the first adhesive.
US Pat. No. 10,167,506

METHOD OF SEQUENCING NUCLEIC ACID COLONIES FORMED ON A PATTERNED SURFACE BY RE-SEEDING

Illumina, Inc., San Dieg...

1. A method of sequencing nucleic acids, the method comprising:(a) contacting a substrate having spatially distinguishable features with a plurality of nucleic acids to seed a subset of the features, thereby generating a seeded subset;
(b) amplifying the nucleic acids in the seeded subset to form nucleic acid colonies;
(c) repeating steps (a) and (b) to increase the number of seeded features, thereby generating an array of nucleic acid colonies; and
(d) sequencing the array of nucleic acid colonies.
US Pat. No. 10,167,507

METABOLIC DISEASES-RELATED ODORANT RECEPTOR GENES AND USE THEREOF

INDUSTRY-ACADEMIC COOPERA...

1. A method of screening for a candidate therapeutic composition that may be useful for treating a metabolic disease, induced by high fat diet (HFD), selected from the group consisting of dyslipidemia, fatty liver and insulin resistance syndrome, comprising:(a) contacting a sample of interest for analysis with a fat cell or muscle cell comprising the nucleotide sequence of SEQ ID NO:25; and
(b) analyzing the expression level of the nucleotide sequence in the cell,
wherein when the expression level of the nucleotide sequence of SEQ ID NO:25 is increased by the sample to he analyzed more than 2-fold from the level before treatment with the sample, then the sample is determined to be a candidate therapeutic composition that may be useful for treating the HFD induced metabolic disease.
US Pat. No. 10,166,740

METHODS OF FORMING METALLIC GLASS MULTILAYERS

Glassimetal Technology, I...

1. A method of forming a multilayer of metallic glass, the method comprisingproviding a base layer of the metallic glass formed of an alloy having thickness do, and initial temperature To, wherein the alloy has a critical cooling rate Rc and a time to crystallize at different temperatures upon heating the metallic glass formed of the alloy th(T);
selecting a thickness di and initial temperature Ti for a molten layer of the alloy such that:
(i) an interface temperature Ts determined by the Half-Enthalpy criterion is at least as high as the glass transition temperature Tg of the metallic glass formed of the alloy,
(ii) a characteristic cooling rate of the molten layer given by ?l?2(Ti?Ts)/4di2, where (?l=3×10?6 m2/s, is greater than Rc, and
(iii) a characteristic time scale of the base layer given by 4do2/?o?2, where ?o=3×10?6 m2/s, is shorter than th(T) at the interface temperature Ts,
depositing the molten layer with the thickness di and initial temperature Ti over the base layer forming a multilayer.
US Pat. No. 10,167,509

ANALYSIS OF NUCLEIC ACIDS

Bio-Rad Laboratories, Inc...

1. A method of identifying a plurality of target nucleic acids as being present on the same polynucleotide, the method comprising:a) separating a sample comprising a plurality of polynucleotides into a first subsample and a second subsample, wherein the polynucleotides comprise a first target nucleic acid and a second target nucleic acid;
b) contacting only the first subsample of the first and second subsamples with an agent capable of physically separating the first target nucleic acid from the second target nucleic acid if both target nucleic acids are present on the same polynucleotide;
c) following step b, separating the first subsample into a first set of partitions;
d) determining a first number of partitions in the first set of partitions that comprise at least one of the target nucleic acids, or a first number of partitions in the first set of partitions that comprise both of the target nucleic acids;
e) separating the second subsample into a second set of partitions;
f) determining a second number of partitions in the second set of partitions that comprise at least one of the target nucleic acids, or a second number of partitions in the second set of partitions that comprise both of the target nucleic acids; and
g) comparing a first value corresponding to the first number obtained in step d with a second value corresponding to the second number obtained in step f to determine whether the first target nucleic acid and the second target nucleic acid are present within the same polynucleotide;
wherein the first and second numbers both represent partitions that comprise at least one of the target nucleic acids or both represent partitions that comprise both of the target nucleic acids.
US Pat. No. 10,166,230

TREATMENT OF VASOMOTOR SYMPTOMS

1. A method for the treatment of vasomotor symptoms associated with menopause comprising the administration to a patient in need of such treatment a therapeutically effective amount of flibanserin, or a pharmacologically acceptable acid addition salt, hydrate or solvate, thereof, wherein said vasomotor symptoms are selected from the group consisting of night sweats, mood swings, and irritability.
US Pat. No. 10,166,742

METAL-POLYAMIDE/POLYETHYLENE-METAL LAMINATE

USINOR, Puteaux (FR) THY...

1. A metal laminate comprising between two outer metal sheets an adhesive polymer layer, characterized in that the adhesive polymer layer comprises a single polymer component, wherein the single polymer component consists of a polyamide, a copolymer of ethylene and an unsaturated carboxylic acid and/or a derivative thereof, a reactive copolymer comprising a styrene-maleic acid anhydride copolymer having a molecular weight of 1400 to 10,000, and an optional epoxy resin.
US Pat. No. 10,166,231

FREEZE DRIED DRUG NANOSUSPENSIONS

Janssen Pharmaceutica NV,...

1. A freeze-dried nanosuspension comprising4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof,
a steric stabilizer which is a solid at room temperature and which is a poloxamer, and
polyvinyl pyrrolidone;
wherein the freeze dried nanosuspension has a re-dispersibility index of at least 90% after storage for 3 months at 25° C.
US Pat. No. 10,167,512

LEUKOCYTE MICRORNAS FOR USE IN DIAGNOSIS AND TREATMENT OF ENDOMETRIOSIS

University of South Carol...

1. A method for diagnosing and/or treating endometriosis in a subject comprising:obtaining a peripheral blood sample from a subject;
isolating peripheral blood mononuclear cells from the peripheral blood sample;
purifying a total RNA sample from the peripheral blood mononuclear cells;
analyzing the total RNA sample from the subject to determine a quantity of each leukocyte microRNA of a set of leukocyte microRNAs present in the total RNA sample, wherein the set of leukocyte microRNAs comprises microRNA-1246, microRNA-1225-5p, microRNA-223, microRNA-451, microRNA-572, microRNA-143, microRNA-505, microRNA-155, microRNA-1281, microRNA-93, microRNA-181a-2, microRNA-181a, microRNA-342-5p, microRNA-21, microRNA-339-3p, microRNA-150, microRNA-17, microRNA-181b, microRNA-501-3p, microRNA-27a, microRNA-23a, microRNA-99b, microRNA-342-3p, let-7e, microRNA-769-5p, microRNA-320c, microRNA-1280, microRNA-766, and microRNA-339-5p;
comparing the quantity of each of the leukocyte microRNAs of the set to control quantities of each of the leukocyte microRNAs;
determining based upon the comparison that each of microRNA-1246, microRNA-1225-5p, microRNA-223, microRNA-451, microRNA-572, and microRNA-143, is overexpressed in the total RNA sample by a factor of about 3 or greater;
determining based upon the comparison that each of microRNA-505, microRNA-155, microRNA-1281, microRNA-93, microRNA-181a-2, microRNA-181a, microRNA-342-5p, microRNA-21, microRNA-339-3p, microRNA-150, microRNA-17, microRNA-181b, microRNA-501-3p, microRNA-27a, microRNA-23a, microRNA-99b, microRNA-342-3p, let-7e, microRNA-769-5p, microRNA-320c, microRNA-1280, microRNA-766, and microRNA-339-5p, is underexpressed in the total RNA sample by a factor of about 3 or greater; and
diagnosing the subject with endometriosis and/or administering a treatment for the endometriosis to the subject.
US Pat. No. 10,166,233

OUTPATIENT MODIFIED RAPID DETOXIFICATION FOR ADDICTION TO ALCOHOL AND DRUGS

1. A method of patient detoxification from a drug addiction on an outpatient basis, comprising administering a plurality of detoxification medicaments comprising:phenobarbital; clonidine; baclofen; ropinirole; and dicyclomine.
US Pat. No. 10,167,516

SIX-GENE BIOMARKER OF SURVIVAL AND RESPONSE TO PLATINUM BASED CHEMOTHERAPY IN SERIOUS OVARIAN CANCER PATIENTS

Wisconsin Alumni Research...

1. A method of treating a subject having ovarian cancer, the method comprising the steps of:(a) obtaining a first sample from the subject prior to treatment for ovarian cancer,
(b) measuring the expression level of AKT2, KRAS, RAC1, and CALM3 in the sample from (a),
(c) obtaining a second sample from the subject after treatment for ovarian cancer,
(d) measuring the expression level of AKT2, KRAS, RAC1, and CALM3 in the sample from (c),
(e) detecting an increased level of expression of the genes in the second sample, as compared to the level of expression of the genes in the first sample, wherein the increased level of expression is at least 1%,
(f) diagnosing the subject as in need of alternative therapy, and
(g) administering to the diagnosed subject an alternative therapy selected from the group consisting of taxane, bevacizumab, docetaxel, doxorubicin, gemcitabine, pemetrexed, tamoxifen, topotecan, and mixtures thereof.
US Pat. No. 10,167,517

MIPOL1-ETV1 GENE REARRANGEMENTS

THE REGENTS OF THE UNIVER...

1. A method for detecting a MIPOL1-ETV1 genetic rearrangement and one or more markers associated with prostate cancer in a biological sample, the method comprising:a) contacting a biological sample with:
i) a probe directly labeled with a detectable label and comprising a sequence that is complementary to a junction at which an ETV1 gene is inserted into a MIPOL1 gene; or
ii) a first probe directly labeled with a detectable label and comprising a sequence complementary to a MIPOL1 gene and a second probe directly labeled with a detectable label and comprising a sequence complementary to an ETV1 gene; or
iii) a first amplification oligonucleotide comprising a sequence complementary to a MIPOL1 gene, a second amplification oligonucleotide comprising a sequence complementary to an ETV1 gene, and a probe directly labeled with a detectable label and comprising a sequence complementary to the product produced from the first and second primers; and
b) detecting in the biological sample expression of a marker selected from the set of markers consisting of AMACR/P504S, PCA3, PCGEM1, prostein/P501S, P503S, P504S, P509S, P510S, prostase/P703P, P710P, prostate specific antigen (PSA), prostatic acid phosphatase (PAP), prostate binding protein (PBP), ABCC5(MDR5), ADAMTS1, AMACR, ANNEXINA11, ANNEXINA1, ANNEXINA4, APP, ARHB, ASNS, ATF2, C1S, C4BPA, C7, CATHEPSINB, CATHEPSINH, CAVEOLIN2, CCND2, CFLAR, CLUSTERIN, COL15A1, COL1A2, COL3A1, c-terminal binding protein, CTBP1, CTBP2, CYSTATINC, E2EPF, EDNRB, EGR1, EPHA1, ETS2, EZH2, FASN, FAT, FHL1, FIBRONECTIN1, FKBP5, FLS353, FOLH1, FOSB, FZD7, GELSOLIN, GP73, GSTM1, GSTM3, GSTM5, GSTP1, HEPSIN, HEVIN, IGFBP3, IGFBP5, IL1R1, IL1R2, ITGA1, ITGB4, ITM2C, JUN, KERATIN5, LIMK1, LUMICAN, MADH4, MAP3K10, MAPK6, MCAM, MEIS1, MEIS2, MMECD10, MOESIN, MPDZ, MTA1, MYBL2, MYLK, NBL1, NCK1, NRAS, PCM1, pim-1, PLA2G2A, PP1CB, PPP2CB, PRKCL2, PSG9, RAB2, RAB5A, RAP2, RIG, S100A11, SCYA2, SEPP1, SGK, SKI, SLUG, TACC1, TASTIN, TBXA2F, TBXA2R, TFCP2, THROMBOSPONDIN1, TIMP2, TNFS10, TNFSF10, TOP2A, TRAF4, TRAP1, UBCH10, VAV2, VIMENTIN, VINCULIN, and YWHAB.
US Pat. No. 10,167,519

FUSION GENES ASSOCIATED WITH PROGRESSIVE PROSTATE CANCER

1. A method of treating a subject, comprising (i) determining whether a subject is at increased risk of manifesting progressive prostate cancer comprising determining whether a prostate cancer cell of the subject contains a SLC45A2-AMACR fusion gene; and (ii) where the cell contains the SLC45A2-AMACR fusion gene so that the subject is at increased risk, performing one or more of cryotherapy, radiation therapy, chemotherapy, hormone therapy, and radical prostatectomy.
US Pat. No. 10,167,520

UNIVERSAL OR BROAD RANGE ASSAYS AND MULTI-TAG SAMPLE SPECIFIC DIAGNOSTIC PROCESS USING NON-OPTICAL SEQUENCING

1. A method for determining the identity of one or more microorganisms in a sample comprising the steps of:(a) isolating DNA or RNA from the sample;
(b) combining the DNA or RNA directly with one or more universal amplification primers, wherein the one or more universal amplification primers are specific for one or more microorganisms;
(c) amplifying the DNA, or the RNA following reverse transcription with a reverse transcriptase, wherein the universal amplification primers for the step of amplifying the DNA, or the RNA following reverse transcription with a reverse transcriptase, are SEQ ID NOS: 83 and 84, and further comprising amplifying with one or more primers specific for at least one of 23s ribosomal nucleic acids, nirS, rpoB, COX1, rbcL, LSU, 28S, fusA, ileS, lepA, leuS, pyrG, recA, recG, rplB, or SSU;
(d) contacting the amplification products of step (c) with one or more microorganism-specific detectable markers, wherein each detectable marker is a non-optical detectable marker;
(e) detecting the amplification products of step (c) with a non-optical detector; and
(f) determining both the presence or absence of the microorganism in the sample, and a copy number of the microorganism when the microorganism of the one or more target microorganisms is present.
US Pat. No. 10,167,521

METHODS AND MATERIALS FOR DETECTING CONTAMINATED FOOD PRODUCTS

Cascade Biosystems, Inc.,...

1. A kit for assessing a food product for contamination, wherein said kit comprises:(a) probe nucleic acid comprising a nucleotide sequence complementary to a sequence of a target nucleic acid present within a microorganism or virus, wherein at least a portion of said target nucleic acid is capable of hybridizing to at least a portion of said probe nucleic acid to form a double-stranded portion of nucleic acid comprising a restriction endonuclease cut site, wherein said probe nucleic acid comprises a restriction endonuclease, and
(b) signal expansion nucleic acid comprising an amplifying restriction endonuclease, a label, and a double-stranded portion of nucleic acid comprising a restriction endonuclease cut site of said restriction endonuclease of said probe nucleic acid.
US Pat. No. 10,167,522

NUCLEIC ACID PROBES AND METHODS FOR DETECTING PLASMODIUM KNOWLESI

ID-Fish Technology, Inc.,...

1. A method for detecting the presence of Plasmodium knowlesi in a sample, said method comprising the steps of:a) contacting said sample with a labeled nucleic acid probe suitable for detecting Plasmodium knowlesi in a hybridization assay, the probe consisting of a labeled nucleic acid sequence consisting of SEQ ID NO: 3 and/or SEQ ID NO: 4 and/or SEQ ID NO:5, or full-length complementary sequences thereof, under conditions that permit said probe to hybridize to Plasmodium knowlesi nucleic acid, wherein any said label is selected from one or more of radioisotopes, biotin, digoxigenin, fluorochromes, modified nucleotides and enzymes; and
b) detecting said probe bound to said Plasmodium knowlesi nucleic acid in said sample as an indication of the presence of Plasmodium knowlesi in said sample.
US Pat. No. 10,167,523

GENE IMPACTING BIOMASS FORMATION AND RECALCITRANCE AND METHODS OF USE

UT-Battelle, LLC, Oak Ri...

1. A method for increasing biomass, cellulose content or sugar release in a Populus plant, the method comprising:(i) transforming Populus plants with a recombinant binary vector comprising a DNA expression construct, wherein the DNA expression construct comprises a heterologous promoter operably linked to a first DNA segment of 100-500 nucleotides long that corresponds to at least a portion of the 3? UTR region of the IQD1 gene as set forth in SEQ ID NO: 1, a spacer segment and a second DNA segment that is fully complementary to the first DNA segment, wherein the first and second DNA segments are arranged in a 5? to 3? direction, respectively, in the DNA expression construct;
(ii) expressing said DNA construct to produce double stranded with hairpin loop RNAi inhibitory molecule in said transformed Populus plants, and wherein expression of endogenous IQD1 gene and its encoded IQD1 protein in said Populus plants is reduced;
and
(iii) selecting a transformed Populus plant from transformed Populus plants of step (ii) which expresses said RNAi inhibitory molecule and exhibits increase in biomass, cellulose content or sugar release as compared to a wild-type untransformed Populus plant species lacking said DNA expression construct.
US Pat. No. 10,166,244

TARGETING NCCA-ATP CHANNEL FOR ORGAN PROTECTION FOLLOWING ISCHEMIC EPISODE

University of Maryland, B...

1. A method of treating or reducing ischemic damage in a subject comprising administering an inhibitor of an NCCa-ATP channel that is a SUR1 antagonist and/or a TRPM4 antagonist as a loading bolus dose followed by a constant infusion of a maintenance dose, wherein the bolus dose is 30-90 times the amount of the maintenance dose.
US Pat. No. 10,167,526

METHODS AND SYSTEMS FOR PREDICTING WHETHER A SUBJECT HAS A CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) LESION FROM A SUSPENSION SAMPLE OF CERVICAL CELLS

IncellDx, Inc., San Carl...

1. A method comprising:(a) receiving a cell suspension sample of cervical cells, comprising endocervical cells and ectocervical cells;
(b) fixing and permeabilizing the cervical cells of the sample;
(c) contacting the fixed and permeabilized cervical cells with a fluorescent DNA-staining reagent and fluorescent probes for HPV E6 and E7 mRNA to produce a labeled sample of cervical cells; and
(d) flow-cytometrically assaying the labeled sample of cervical cells on a flow cytometer to obtain at least:
i) a nuclear to cytoplasmic ratio of the cervical cells based on the fluorescent DNA-staining reagent,
ii) a quantification of HPV E6 and E7 mRNA expression of the cervical cells based on the fluorescent probes, and
iii) a cell cycle identification of the cervical cells based on the fluorescent DNA-staining reagent; and
(e) obtaining from the flow cytometer a determination, based on the nuclear to cytoplasmic ratio, the quantification of HPV E6 and E7 mRNA and the cell cycle identification, of whether a cell of a CIN lesion is present in the sample.
US Pat. No. 10,165,737

WARM CLOUD CATALYST, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

Yougui Yan, Kunming (CN)...

1. A warm cloud catalyst, comprising following components in parts by weight:80-120 parts of a plant ash/plant powder/plant carbon powder;
0.5-5 parts of a surfactant dry powder or 15-32 parts of a surfactant solution; and
2-10 parts of a thickening agent.
US Pat. No. 10,166,505

METHOD OF TREATING GAS AND GAS TREATMENT DEVICE

CHING-JING PHOTONERGY CO....

1. A method of treating a gas, the gas comprising a nitrous oxide (N2O), the method comprising the steps of:delivering the gas to a first chamber 10, followed by supplying a first energy 11 to the first chamber 10, so as for the gas to form an excited-state ionized gas, wherein the ionized gas comprises a nitric oxide (NO) and a nitrogen atom (N);
supplying an ozone (O3) to a second chamber 20, wherein the second chamber 20 has a second energy whereby the ozone forms an excited-state oxygen atom (O);
delivering the excited-state ionized gas of the first chamber 10 and the excited-state oxygen atom of the second chamber to a third chamber 30 to allow a reaction to occur between the excited-state ionized gas and the excited-state oxygen atom such that the gas in the third chamber 30 comprises a nitrogen dioxide (NO2); and
delivering the gas of the third chamber 30 to a fourth chamber 40, wherein the fourth chamber 40 has a scrubbing system 41, and the scrubbing system 41 contains a solvent 411 for dissolving nitrogen dioxide (NO2).
US Pat. No. 10,166,251

STAT5A AND ITS FUNCTIONAL TUMOR SUPPRESSOR ANALOGS FOR TREATMENT OF MALIGNANCIES EXPRESSING NPM/ALK AND OTHER ONCOGENIC KINASES

THE TRUSTEES OF THE UNIVE...

1. A method of treating malignancies expressing an ALK+chimeric tyrosine kinase in a subject, comprising the step of administering to the subject a composition comprising a therapeutically effective amount of a small molecule chemical compound, wherein the small molecule chemical compound is a DNA Methyltransferase (DNMT) inhibitor.
US Pat. No. 10,166,252

METHOD FOR ASSESSING AND TREATING OR PREVENTING IMPAIRED PLASMA POLAR LIPID LEVELS

N.V. NUTRICIA, Zoetermee...

1. A method for treating, inhibiting, suppressing, and/or decreasing impaired plasma levels of one or more polar lipids selected from the group consisting of C16:1CE; C18:3CE; C20:4CE; PI(34:1); PI(38:2); PI(38:4); C16:0CE; C18:2CE; PA(34:3); PE(36:0); PE(38:0); aePC(36:0); aePC(38:0); aePC(38:4); aePC(40:4); lPC(18:0); lPC(18:3); lPC(20:4); PC(36:1); PC(38:0); PC(38:4); PC(40:4); DSM(18:0); aePC(32:1); aePC(32:2); aePC(34:0); PC(44:2); SM(16:0); SM(18:0); SM(22:0); SM(24:0); SM(24:1); aePC(36:5); aePC(38:5); aePC(40:5); lPC(20:5); lPC(22:5); PC(36:5); PC(38:5); PC(40:5); PI(38:5); PI(40:5); C20:5CE; C22:6CE; aePC(38:6); aePC(40:6); aePE(40:6); PC(36:6); PC(38:6); PC(40:6); PC(42:6); PI(40:6); C22:5CE; aePE(38:6); lPE(22:6); PE(38:6); PE(40:6); PI(38:6); PC(40:7); PC(40:8); PC(42:10); PC(42:7); PC(42:8); PC(42:9); PE(40:7); lPC(22:6); C19:0CE; C19:1CE; C20:0CE; C20:1CE; C20:3CE; PE(34:1); PE(34:2); PE(36:1); PE(36:2); PE(36:3); PE(36:4); PE(38:3); PE(38:4); PE(40:4); PI(36:3); PI(38:3); PS(38:4); aePC(36:1); aePC(38:1); aePC(38:2); aePC(38:3); aePC(40:2); aePC(40:3); lPC(20:3); PC(34:3); PC(36:3); PC(38:1); PC(38:2); PC(40:3); and PE(40:5) in a subject with Alzheimer's Disease (AD) or mild cognitive impairment (MCI), the method comprising administering to the subject a composition comprising:(a) at least one B vitamin selected from the group consisting of vitamin B6, vitamin B12 and vitamin B9; and
(b) one or more of uridine and cytidine, or salts, phosphates or esters thereof.
US Pat. No. 10,166,253

POSITIVELY CHARGED CO-POLYMERS FOR USE AS ANTIMICROBIAL AGENTS

Region Midtjylland, Vibo...

1. A method for treating, ameliorating, or preventing bacterial infections with Escherichia coli, Pseudomonas aeruginosa, or Staphylococcus aureus, said method comprising administration of an effective amount of a composition comprising a glatiramer acetate copolymer to an individual in need thereof.
US Pat. No. 10,166,254

USE OF MESENCHYMAL STEM CELL-EDUCATED MACROPHAGES TO TREAT AND PREVENT GRAFT VERSUS HOST DISEASE AND RADIATION-INDUCED INJURY

Wisconsin Alumni Research...

1. A method for treating bone marrow failure in a subject exposed to ionizing radiation, the method comprising administering to the subject a therapeutically effective amount of human IL-6 high, IL-10 high, IL-12 low, and TNF-? low mesenchymal stem cell-educated macrophages (MEMs), whereby the MEM-administered subject maintains production of white blood cells and platelets after exposure to ionizing radiation.
US Pat. No. 10,167,535

MAGNESIUM CASTING ALLOY AND METHOD OF MANUFACTURING SAME

HONDA MOTOR CO., LTD., T...

1. A magnesium casting alloy comprising Mg, Zn and Y,wherein a content of Zn is at least 1.2 atomic % but no more than 4.0 atomic %,
a content of Y is at least 1.2 atomic % but no more than 4.0 atomic %,
a composition ratio Zn/Y of Zn to Y is at least 0.9 but no more than 1.1,
an Mg purity of an Mg mother phase is at least 97.0%, and
a thermal conductivity is at least 80.0 W/m·K.
US Pat. No. 10,165,743

RHIZOBACTERIAL STRAIN AND USES FOR ENHANCING TOTAL LIPID YIELDS IN AN OILSEED CROP


wherein the Pseudomonas fluorescens strain is in association with a biologically acceptable carrier; and
wherein the Pseudomonas fluorescens strain increases total lipid yields in the oilseed crop relative to oilseed crop not exposed to the Pseudomonas fluorescens strain.
US Pat. No. 10,166,255

INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF THERAPY

REGENTS OF THE UNIVERSITY...

1. A method of making an engineered population of primary cells comprising:a) introducing into a population of primary cells a ribonucleic acid encoding for at least a portion of an exogenous functional T cell receptor sequence or encoding for at least a portion of an exogenous functional chimeric antigen receptor sequence;
b) reverse transcribing said ribonucleic acid, thereby producing a deoxyribonucleic acid encoding for said at least a portion of an exogenous functional T cell receptor sequence or said at least a portion of an exogenous functional chimeric antigen receptor sequence; and
c) introducing said deoxyribonucleic acid into a genomic break comprising at least a portion of a cytokine inducible SH2-containing protein (CISH) gene in a genome of at least one cell in said population of primary cells, wherein said genomic break is performed by an endonuclease and partially reduces or completely suppresses expression of said CISH gene.
US Pat. No. 10,166,256

ANTI-TUMOR T CELL IMMUNITY INDUCED BY HIGH DOSE RADIATION

The Board of Trustees of ...

1. A method for treating a cancer in a subject, the method comprising:a. activating T cells with a high dose of localized radiation at a tumor site;
b. collecting a population of cells comprising the activated T cells; and
c. administering the collected population of cells to the subject, thereby treating the cancer.
US Pat. No. 10,166,257

PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY

IOVANCE BIOTHERAPEUTICS, ...

1. A method for treating a subject with cancer, the method comprising administering expanded tumor infiltrating lymphocytes (TILs) comprising:(a) obtaining a first population of TILs from a tumor resected from a subject by processing a tumor sample obtained from the subject into multiple tumor fragments;
(b) adding the tumor fragments into a closed system;
(c) performing a first expansion by culturing the first population of TILs in a cell culture medium comprising IL-2 to produce a second population of TILs, wherein the first expansion is performed in a closed container providing a first gas-permeable surface area, wherein the first expansion is performed for about 3-11 days to obtain the second population of TILs, wherein the second population of TILs is at least 50-fold greater in number than the first population of TILs, and wherein the transition from step (b) to step (c) occurs without opening the system;
(d) performing a second expansion by supplementing the cell culture medium of the second population of TILs with additional IL-2, OKT-3, and antigen presenting cells (APCs), to produce a third population of TILs, wherein the second expansion is performed for about 7-11 days to obtain the third population of TILs, wherein the third population of TILs is a therapeutic population of TILs which comprises an increased subpopulation of effector T cells and/or central memory T cells relative to the second population of TILs, wherein the second expansion is performed in a closed container providing a second gas-permeable surface area, and wherein the transition from step (c) to step (d) occurs without opening the system;
(e) harvesting the therapeutic population of TILs obtained from step (d), wherein the transition from step (d) to step (e) occurs without opening the system;
(f) transferring the harvested TIL population from step (e) to an infusion bag, wherein the transfer from step (e) to (f) occurs without opening the system;
(g) cryopreserving the infusion bag comprising the harvested TIL population from step (f) using a cryopreservation process; and
(h) administering a therapeutically effective dosage of the third population of TILs from the infusion bag in step (g) to the subject.
US Pat. No. 10,167,538

STEEL PIPE

1. A steel pipe, consisting of, in terms of mass %:0.06% to 0.25% of C,
0.50% or less of Si,
1.00% to 1.80% of Mn,
0.030% or less of P,
0.020% or less of S,
0.08% or less of Al,
0.008% or less of N,
0.080% or less of Nb, and
a remainder consisting of Fe and unavoidable impurities,
wherein a compressive residual stress at an outer surface measured by an X-ray method is 250 MPa or more,
a compressive residual stress at a position at a depth of 1 mm from the outer surface measured by the X-ray method is 70% or more of the compressive residual stress at the outer surface measured by the X-ray method, and
having a wall thickness of from 7 mm to 17 mm, wherein a ratio of the wall thickness to an outer diameter (wall thickness/outer diameter) is from 0.07 to 0.12.
US Pat. No. 10,166,258

COMPOSITIONS CONTAINING PLATELET CONTENTS

Mayo Foundation for Medic...

1. A method for expanding a cell population comprising culturing a first population of cells in the presence of medium comprising a platelet lysate composition under conditions wherein said first population of cells is expanded to a second population of cells having more cells than said first population, wherein said platelet lysate composition comprises, plasma and a total protein concentration of at least about 35 mg/mL, a filtrate from a lysed platelet preparation passed through a 0.45 ?m or smaller filter and comprises greater than 200 pg of VEGF polypeptide per ml and wherein said platelet lysate composition comprises protein complexes greater than 50 kDa.
US Pat. No. 10,168,307

TUNABLE DIRECTIONAL COLOR TRANSITION COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME

Segan Industries, Inc., ...

1. An edible color change composition comprising:a food-grade ingestible component;
a color former; and
a food-grade color developer that transitions from a first color state to a second color state upon application of an applied stimulus.
US Pat. No. 10,165,747

MAIZE INBRED PH41VW

PIONEER HI-BRED INTERNATI...

1. A seed, plant, plant part, or plant cell of inbred maize variety PH41VW, representative seed of the variety having been deposited under ATCC accession number PTA-124770.
US Pat. No. 10,166,259

ISOLATION OF EXOSOMES FROM COLOSTRUM POWDER AND EXOSOMAL DRUG FORMULATIONS USING THE SAME

3P Biotechnologies, Inc.,...

1. A method for isolation of purified exosomes from colostrum powder, the method comprising:a. providing a sample of either standardized bovine colostrum powder or standardized caprine colostrum powder;
b. suspending the colostrum powder in water and agitating to produce a uniform suspension;
c. subjecting the colostrum powder suspension to centrifugation at a first predetermined G-force to produce a first supernatant and collecting the first supernatant;
d. subjecting the first supernatant from step (c) to centrifugation at a second predetermined G-force to produce a second supernatant and collecting the second supernatant;
e. subjecting the second supernatant from step (d) to centrifugation at a third predetermined G-force to produce an exosomal pellet and collecting the exosomal pellet;
f. washing the exosomal pellet in de-ionized water; and,
g. suspending the exosomal pellet which contains the isolated purified exosomes in phosphate-buffered-saline (PBS), wherein the purified exosome yield is at least 8-times greater than if the exosomes were isolated from milk.
US Pat. No. 10,165,748

MAIZE INBRED PH42AN

PIONEER HI-BRED INTERNATO...

1. A seed, plant, plant part, or plant cell of inbred maize variety PH42AN, representative seed of the variety having been deposited under ATCC accession number PTA-124771.
US Pat. No. 10,166,260

WOUND CARE PRODUCT WITH EGG SHELL MEMBRANE

Blaine Laboratories, Inc....

1. A wound care gel, comprising:a) irradiated egg shell membrane comprising protein, wherein said irradiated egg shell membrane is present in an amount of about 0.1 to about 10% by weight;
b) an antimicrobial compound in an amount of about 0.001 to about 0.1% by weight;
c) an effective amount of a tissue growth accelerator; and optionally
d) inactive ingredients;
wherein said wound care gel is obtained by:
i. mixing the irradiated eggshell membrane with an aqueous phase to provide a protein solution;
ii. partially neutralizing the protein solution by adding carbomer to provide a partially neutralized protein gel;
iii. optionally adding glycerin to the partially neutralized protein gel;
iv. adding triethanolamine to the partially neutralized protein gel of step ii) or step iii) to provide a neutralized gel;
v. adding the antimicrobial compound to the neutralized gel;
vi. adding the tissue growth accelerator; and optionally
vii. adding inactive ingredients.
US Pat. No. 10,166,005

MEDICAL DEVICES WITH COATINGS FOR ENHANCED ECHOGENICITY

Encapson B.V., Enschede ...

1. A medical device comprising a coating for ultrasound detection, said coating comprising microparticles that are visible with ultrasound, wherein the microparticles are solid microspheres comprising glass or silicate, and wherein the diameter of at least 60% of said microparticles on said medical device is between 22 and 45 ?m and wherein the density of said microspheres on the surface of said medical device is between 45 and 450 microspheres/mm2, and wherein at least one of the following conditions a) -e) is met;a) the diameter of at least 60% of the microspheres on the medical device is between 22 and 27 ?m and the density of the microspheres on the surface of the medical device is between 150 and 450 microspheres/mm2;
b) the diameter of at least 60% of the microspheres on the medical device is between 27 and 32 ?m and the density of the microspheres on the surface of the medical device is between 70 and 450 microspheres/mm2;
c) the diameter of at least 60% microspheres on the medical device is between 32 and 38 ?m and the density of the microspheres on the surface of the medical device is between 45 and 225 microspheres/mm2;
d) the diameter of at least 60% of the microspheres on the medical device is between 38 and 45 ?m and the density of the microspheres on the surface of the medical device is between 45 and 150 microspheres/mm2; and
e) the diameter of at least 60% of the microspheres on the medical device is between 22 and 32 ?m and the density of the microspheres on the surface of the medical device is between 150 and 450 microspheres/mm2.
US Pat. No. 10,166,262

STRAIN OF BACTERIA AND COMPOSITION COMPRISING THE SAME

1. A composition comprising a strain of Lactobacillus plantarum AMT 14 bacteria (PCM Accession No. B/00092) in an amount of 101 to 1013 of colony forming units cfu/ml, a medium, and a bulking agent.
US Pat. No. 10,165,751

CANOLA INBRED LINE G30853A

Agrigenetics, Inc., Indi...

1. A seed of canola cultivar designated G30853A, wherein a representative sample of seed of said cultivar was deposited under ATCC Accession No. PTA-122718.
US Pat. No. 10,165,752

MAIZE INBRED PH2RTF

PIONEER HI-BRED INTERNATI...

1. A seed, plant, plant part, or plant cell of inbred maize variety PH2RTF, representative seed of the variety having been deposited under ATCC accession number PTA-124800.
US Pat. No. 10,166,520

CATCAPSULES FOR SELF-HEALING APPLICATIONS

International Business Ma...

1. A method of making a linked microcapsule, comprising:providing a first microcapsule having a first payload agent inside the first microcapsule and a first orthogonal-functionalized unit incorporated into a wall of the first microcapsule;
providing a second microcapsule having a second payload agent inside the second microcapsule and a second orthogonal-functionalized unit incorporated into a wall of the second microcapsule; and
forming a linked microcapsule by reacting:
(a) the first microcapsule with the second microcapsule in an acyclic diene metathesis reaction,
(b) the first microcapsule with the second microcapsule in a thiol-ene click reaction,
(c) the first microcapsule with the second microcapsule in a thiol-yne click reaction,
(d) the first microcapsule with the second microcapsule in a thiol-epoxy click reaction,
(e) the first microcapsule with the second microcapsule in a Michael reaction, or
(f) a mixture of an isocyanate, the first microcapsule, and the second microcapsule.
US Pat. No. 10,166,265

PHARMACEUTICAL COMPOSITION FOR TREATING BACTERIAL AND VIRAL INFECTIONS

1. A pharmaceutical composition comprising an amount of vitamin C, zinc, vitamin A, vitamin D3, vitamin B6, garlic and Echinacea effective to treat bacterial and/or viral infections.
US Pat. No. 10,166,266

PROCESS TO ENHANCE THE BIOACTIVITY OF ASHWAGANDHA EXTRACTS

1. A method of treating stress comprising administering an enteric coated composition to a subject in need thereof, the enteric coated composition comprising extract of Withania somnifera and an enteric coating material, wherein the extract of Withania somnifera comprises by weight:at least about 3.5% withanolide glycosides,
less than about 0.1% withanolide aglycones,
less than about 0.1% alkaloids, and,
less than about 0.1% oligosaccharides,
and wherein the enteric coating material is selected from the group consisting of poly (methacrylic acid-co-methyl methacrylate), and, a combination of modified ethyl cellulose and sodium alginate.
US Pat. No. 10,167,291

PHARMACEUTICAL COMPOSITION COMPRISING A CRYSTAL FORM OF (S)-4-(8-AMINO-3-(1-(BUT-2-YNOYL) PYRROLIDIN-2-YL)IMIDAZO[1,5-A]PYRAZIN-1-YL)-N-(PYRIDIN-2-YL)BENZAMIDE

Acerta Pharma B.V., Oss ...

1. A solid pharmaceutical composition comprising at least one pharmaceutically acceptable excipient and 95-105 mg of a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide characterized by a reflection X-ray powder diffraction pattern comprising peaks at 6.4° ±0.2° 2?, 8.6°±0.2° 2?, 10.5° ±0.2° 2?, 11.6° ±0.2° 2? and 15.7° ±0.2° 2?.
US Pat. No. 10,166,267

MULTI-COMPONENT FORMULATIONS FOR THE TREATMENT OF COGNITIVE DECLINE INCLUDING ALZHEIMER'S DISEASE

1. A multi-component formulation comprising:about 0.01% to about 5% by weight methylsulfonylmethane,
about 5% to about 99% by weight fructose 1,6-diphosphate, and
about 0.01% to about 95% by weight of at least one of an herbal component or a nutritional component comprising curcumin.
US Pat. No. 10,166,269

COMBINATIONS OF PROTEASOME INHIBITORS AND CYCLIC PEPTIDES

BIG DNA LTD, Roslin, Mid...

1. A combination comprising: (i) a proteasome inhibitor or a pharmaceutically acceptable salt thereof; and (ii) a cyclic peptide or a pharmaceutically acceptable salt thereof, wherein the cyclic peptide or a pharmaceutically acceptable salt thereof comprises an exposed Arg-Gly-Asp (RGD) moiety; and wherein the ratio of the proteasome inhibitor or a pharmaceutically acceptable salt thereof to the cyclic peptide or a pharmaceutically acceptable salt thereof ranges from 1:5000 to 1:10 w/w.
US Pat. No. 10,166,272

EFFICIENT SYSTEMIC TREATMENT OF DYSTROPHIC MUSCLE PATHOLOGIES

GENETHON, Evry (FR) ROYA...

1. A method of treating Duchenne muscular dystrophy (DMD) in a human, comprising:systemically administering by intravascular injection to a human in need thereof a gene therapy product that comprises an adeno-associated viral (AAV) vector of serotype 8 or 9 which harbors a nucleic acid sequence encoding a human ?R4-R23/?CT microdystrophin, thereby treating DMD in the human.
US Pat. No. 10,168,321

COMPOSITION COMPRISING UP-CONVERTING PHOSPHORS FOR DETECTING AN ANALYTE

Roche Diabetes Care, Inc....

1. A detector matrix for detecting at least one analyte in a sample comprising (i) at least one enzyme active in the presence of said at least one analyte and (ii) at least one indicator reagent changing at least one optical property dependent on the activity of said enzyme, wherein the indicator reagent is homogenously distributed within said detector matrix, wherein said detector matrix further comprises (iii) UV-emitting up-converting phosphor particles.
US Pat. No. 10,166,273

SYNERGISTIC TUMOR TREATMENT WITH ANTIBODIES TARGETING PD-1, PD-L1 OR CTLA4 AND INTEGRIN-BINDING-FC-FUSION PROTEIN

The Board of Trustees of ...

1. A method for inhibiting growth and/or proliferation of tumor cells in a subject comprising administering to the subject an effective amount of an integrin-binding-Fc fusion protein, wherein the integrin-binding-Fc fusion protein comprises (i) an integrin-binding polypeptide comprising an integrin-binding loop and a knottin polypeptide scaffold; and (ii) an immunoglobulin Fc domain, wherein the integrin-binding polypeptide is operably linked to the Fc domain, and an immune checkpoint blocker selected from the group consisting of an antibody or antibody fragment targeting PD-1, an antibody or antibody fragment targeting PD-L1, and an antibody or antibody fragment targeting CTLA4.
US Pat. No. 10,168,322

ELECTRONIC ANALYTE ASSAYING DEVICE

1. A diagnostic device for detecting the presence of an analyte in a fluid sample, the device comprising:a housing configured to receive a lateral flow diagnostic strip, said lateral flow diagnostic strip including:
a receiving end for receiving the fluid sample;
a terminal end opposite said receiving end; and
a capture region located between said receiving end and said terminal end; and a processor configured to, upon receiving the fluid sample:
illuminate the lateral flow diagnostic strip;
measure intensity values of light reflected from the lateral flow diagnostic strip;
obtain, during a first time period, a first series of intensity value pairs, wherein each intensity value pair of the first series of intensity value pairs comprises a measurement signal and a background signal, and wherein the measurement signal and the background signal for each intensity value pair of the first series of intensity value pairs are obtained at substantially the same time;
calculate the intensity difference between the measurement signal and the background signal for each pair of the first series of intensity value pairs to generate a first series of intensity difference values;
generate, at the end of the first time period, a fluid front detection result based at least in part on the first series of intensity difference values, wherein the fluid front detection result indicates whether at least a portion of the first series of intensity difference values correspond to a threshold for identifying a fluid front;
obtain, during a second time period, a second series of intensity value pairs, wherein each intensity value pair of the second series of intensity value pairs comprises a measurement signal and a background signal, and wherein the measurement signal and the background signal for each intensity value pair of the second series of intensity value pairs are obtained at substantially the same time;
calculate the intensity difference between the measurement signal and the background signal for each pair of the second series of intensity value pairs to generate a second series of intensity difference values; and
generate, at the end of the second time period, a message indicating that the analyte is present in the fluid sample based at least in part on:
(i) the fluid front detection result generated with the first series of intensity difference values obtained during the first time period, and
(ii) the second series of intensity difference values obtained during the second time period.
US Pat. No. 10,166,274

METHODS FOR TREATING LYSOSOMAL ACID LIPASE DEFICIENCY IN PATIENTS

ALEXION PHARMACEUTICALS, ...

1. A method of treating a human patient suffering from a lysosomal acid lipase (LAL) deficiency, comprising administering to the human patient safe and effective amounts of recombinant human LAL, wherein the administration of safe and effective amounts of recombinant human LAL comprises:a) administering an initial dosage in an amount at 1 mg LAL/kg body weight one or more times, followed by
b) administering a subsequent dosage in an amount of 3 mg LAL/kg body weight one or more times.
US Pat. No. 10,168,323

COMPOSITIONS AND METHODS FOR CAPTURE OF CELLULAR TARGETS OF BIOACTIVE AGENTS

Promega Corporation, Mad...

1. A kit comprising:(a) a cell that expresses a fusion of a bioluminescent reporter and a cellular target of a small molecule bioactive agent, wherein the cellular target is located within a cell;
(b) the small molecule bioactive agent tethered by a carbamate linker to a chloroalkane capture ligand, wherein the small molecule bioactive agent tethered to a chloroalkane capture ligand is cell permeable, and wherein the small molecule bioactive agent is capable of non-covalently binding to the cellular target upon interaction thereof under intracellular conditions; and
(c) a solid surface displaying a capture protein, wherein the capture protein comprises a modified dehalogenase configured to covalently bind to the chloroalkane capture ligand upon interaction thereof.
US Pat. No. 10,166,275

ANTIMICROBIAL COMPOSITION COMPRISING PYROGENIC SILICA AND SERRATHIOPEPTIDASE AND USES THEREOF

Willingsford Limited., S...

1. An antimicrobial composition comprising from 90 to 99% by weight a silicious absorbent made of globules of fine hydrated pyrogenic silica and polysilicic acid (SiO2*H2O); and the remainder by weight, comprising 1 to 10% serrathiopeptidase immobilized thereon; wherein said antimicrobial composition is a dry powder.
US Pat. No. 10,166,531

CATALYST FOR SELECTIVELY CATALYTICALLY OXIDIZING HYDROGEN SULFIDE, CATALYST FOR BURNING TAIL-GAS, AND PROCESS FOR DEEPLY CATALYTICALLY OXIDIZING HYDROGEN SULFIDE TO ELEMENT SULFUR

Nan Yang, Zibo, Shandong...

1. A catalyst for selectively catalytically oxidizing hydrogen sulfide, comprising components of a mass percent of: 13-34% of iron trioxide, 60-72% of anatase titanium dioxide and a balance which are auxiliary agents.
US Pat. No. 10,166,276

COMPOSITIONS AND METHODS FOR TREATMENT OF NON-HODGKINS LYMPHOMA

The Trustees of the Unive...

1. A method of inducing an immune response against a B cell lymphoma in a subject, comprising administering a pharmaceutical composition comprising a fusion polypeptide comprising a fragment of a listeriolysin O (LLO) protein and an antigen, wherein said fragment of an LLO protein is chemically conjugated to said antigen, wherein said antigen is a fragment of a B cell receptor (BCR) comprising the idiotype of said BCR, and wherein said fragment of an LLO protein is an N-terminal fragment comprising the amino acid sequence set forth in SEQ ID NO: 25 or an N-terminal LLO-detox fragment comprising the amino acid sequence set forth in SEQ ID NO: 41.
US Pat. No. 10,167,301

PROCESS FOR THE PREPARATION OF BIS(CHLOROMETHYL)DICHLOROSILANE AND BIS(CHLOROMETHYL)(ARYL)CHLOROSILANE

Dow Global Technologies L...

1. A process for the preparation of bis(chloromethyl)dichlorosilane comprising reacting bis(chloromethyl)diarylsilane and one or more chloride compounds in the presence of one or more Lewis acids in an inert solvent and under an inert atmosphere.
US Pat. No. 10,168,325

NON-SPECIFIC REACTION INHIBITOR

LSI MEDIENCE CORPORATION,...

1. A method for inhibiting a non-specific reaction in an immunological measurement, said method comprising:preparing a sample containing an antigen to be measured;
preparing a solution containing a polymer-modified fragment of an antibody specific to a non-specific reaction factor, wherein the polymer is selected from the group consisting of polyethylene glycol, dextran, bovine serum albumin, and polyglutamic acid, the fragment of the antibody is Fab?, and the non-specific reaction factor is selected from the group consisting of IgM, IgG, IgA, IgE, and IgD;
mixing the solution with the sample to react the polymer-modified fragment with the non-specific reaction factor, before an antibody specific to the antigen is reacted with the antigen, and adding the antibody specific to the antigen to the mixture; and
inhibiting a non-specific reaction caused by the non-specific reaction factor.
US Pat. No. 10,170,121

SPEECH RECOGNITION SYSTEM AND METHOD FOR OPERATING A SPEECH RECOGNITION SYSTEM WITH A MOBILE UNIT AND AN EXTERNAL SERVER

Volkswagen AG, (DE)

1. A transportation vehicle user interface voice recognition system comprising:a mobile unit provided on a transportation vehicle; and
an external server, wherein the mobile unit and the external server are in communication with each other, wherein the mobile unit comprises;
a memory that stores voice model data that comprise at least one expression set with expressions for controlling transportation vehicle functionality using voice input of a user;
a voice recognition unit configured to use the voice model data as a basis for producing a recognized text for captured voice input data generated based on the voice input of the user, wherein the recognized text is analyzed to determine how to control the transportation vehicle functionality; and
a data interface that at least intermittently sets up a data-oriented connection to a data interface of the external server,
wherein the external server comprises:
a database with event data having associated time data and expressions for controlling transportation vehicle functionality, the external server being configured to produce update data for the voice model data stored in the memory of the mobile unit by comparing the time data associated with the event data with a current time,
wherein the update data for the voice model data comprises at least expressions associated with the event data in the external server database,
wherein the external server is further configured to transmit the update data from the external server to the data interface of the mobile unit,
wherein the transmitted expressions are added to the stored at least one expression set based on the update data and a subset of expressions of the at least one expression set stored in the memory are erased from the memory based on the update data, and
wherein the event data of the database further have associated geographical position data, wherein the voice recognition system further includes a position finding unit configured to determine a current position of the mobile unit, wherein position finding unit is configured to transmit the current mobile unit's position to the external server, and wherein the update data are further produced by the external server by comparing the geographical position data associated with the event data with the mobile unit's position.
US Pat. No. 10,168,326

INTERFERENCE-SUPPRESSED IMMUNOASSAY TO DETECT ANTI-DRUG ANTIBODIES IN SERUM SAMPLES

F. HOFFMANN-LA ROCHE INC....

1. An interference-suppressed immunoassay for the detection of anti-drug antibodies against a drug antibody for the treatment of rheumatoid arthritis, juvenile arthritis, or osteoarthritis, said method comprising:(a) incubating a sample from a rheumatoid arthritis, juvenile arthritis, or osteoarthritis patient treated with said drug antibody simultaneously with a mixture comprising 0.5 ?g/ml to 10 ?g/ml of a 1:1 conjugate of said drug antibody to a first member of a binding pair via a single lysine residue as a capture drug antibody and 0.5 ?g/ml to 10 ?g/ml of a 1:1 conjugate of said drug antibody to a detectable label via a single lysine residue as a tracer drug antibody for 0.5 to 24 hours to generate a capture drug antibody/anti-drug antibody/tracer drug antibody complex, wherein the sample comprises 1% to 20% serum and is supplemented with oligomeric human IgG prior to the incubation to a final concentration of 10 ?g/ml to 1000 ?g/ml,
(b) immobilizing the capture drug antibody/anti-drug antibody/tracer drug antibody complex formed in step (a) on a solid phase by covalently or non-covalently conjugating said first member of a binding pair to a second member of a binding pair on the solid phase,
(c) incubating the immobilized complex with an antibody against the detectable label of the tracer drug antibody, conjugated to a second detectable label, and
(d) detecting the anti-drug antibodies against said drug antibody via a signal of the detectable label of the antibody of step (c), and
wherein the drug antibody is an anti-inflammatory antibody.
US Pat. No. 10,166,534

METHOD FOR REDUCTION OF ORGANIC MOLECULES

RHEINISCH-WESTFALISCHE TE...

10. The method according to claim 7, wherein the sulfonic acid is selected from the group consisting of methanesulfonic acid, trifluoromethanesulfonic acid, p-toluenesulfonic acid, p-bromobenzosulfonic acid, p-nitrobenzosulfonic acid, sulfuric acid, hydrochloric acid, hydrofluoric acid, trifluoroacetic acid, perchloric acid, bis(trifluoromethane)sulfonimide and mixtures thereof.
US Pat. No. 10,166,281

METHOD AND COMPOSITION FOR MODULATING IMMUNE RESPONSE

VLP Therapeutics, LLC, W...

1. A method for modulating an immune response against a cancer, wherein said method comprises administering, to a subject with a cancer, an effective amount of a composition comprising an alphavirus virus like particle, wherein said alphavirus virus like particle does not contain a heterologous antigen.
US Pat. No. 10,167,306

CRYSTALLINE FORM OF 1-(BETA-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-FLUOROPHENYL)-2-THIENYLMETHYL]BENZENE AND PREPARATION METHOD THEREOF

SHANGHAI DESANO PHARMACEU...

1. A crystalline form W of 1-(?-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene, wherein the crystalline form W has an X-ray powder diffraction pattern substantially as shown in FIG. 1.